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Thesis Statement 
Prostate cancer (PCa) is a prevalent disease which affects 1 in 6 men in the 
United States and has overtaken lung cancer as the leading cause of cancer 
related deaths in American men and number two worldwide (1). While diagnosis 
and treatment options are improving, there is still a fundamental problem with its 
management. It is unclear which PCa is aggressive (life- threatening) and which 
is non-aggressive (non-life threatening). As a result, overtreatment of PCa results 
from the absence of tools that can properly differentiate between the two. While 
magnetic resonance imaging has become an increasingly valuable tool in the 
management of men with PCa, its use to identify aggressive disease and 
characterize extent have yet to be developed. The ability to identify the extent of 
significant disease would increase the effectiveness of focal therapy including 
cryosurgery and RF ablation which are currently hampered by the absence of 
good information for targeting treatment. Currently available treatments such as 
radiation therapy and surgery address the whole gland, while focal therapies 
treat part of the gland and can more effectively avoid damaging critical 
structures. Improved detection and evaluation of extent will impact areas of 
prostate cancer management by improving biopsy yield especially with the 
growth of MRI targeted biopsies both in the gantry and fused with real-time 
Ultrasound(2).   
Among several diagnostic imaging tests that are available for detection of 
PCa in the market today, Magnetic Resonance Imaging (MRI) occupies a unique 
position due to its excellent soft tissue contrast and its ability to generate tissue 
property dependent multi-parametric data (3). Multi-parametric MRI (MP-MRI) 
refers to the combination of multiple imaging methods and their associated 
xx 
quantitative maps such as apparent diffusion coefficient (ADC) maps from 
diffusion weighted imaging (DWI), pharmacokinetic maps from dynamic contrast 
enhanced MRI (DCE-MRI) and metabolite ratio maps from three dimensional MR 
spectroscopic imaging (3D-MRSI). With DWI, MP-MRI can help in tumor 
identification by mapping areas of restricted diffusion of water molecules that 
indicate micro-structural changes in cellular density. Angiogenesis, the growth of 
new blood vessels, is an indicator of cancerous tissue. Using DCE-MRI, we can 
probe heterogeneous neovascular structure and abnormal vessel permeability 
that is indicative of cancer. 3D-MRSI is another MR technique that detects 
cancer by mapping the chemical composition of the prostate (2,3). MP-MRI has 
been shown to increase sensitivity and specificity compared to any single MRI 
dataset. 
The ability to develop and evaluate MP-MRI to prospectively detect 
disease, assess aggressiveness and delineate extent, first requires the 
retrospective validation against post-surgical pathology sections. Despite the 
large effort made by many groups in this area of research, the correlation of in 
vivo MP-MRI with pathology is still a challenge and to date is insufficient to 
develop highly accurate models of disease. To address this problem this thesis 
showcases: 
1. A novel registration approach called LATIS (Local Affine Transformation
assisted by Internal Structures) for co-registering post prostatectomy
pseudo-whole mount (PWM) pathological sections with in vivo MRI
images. This work is presented in Chapter 3.
2. A MP-MRI based predictive model for disease detection using a
composite biomarker score based on a unique database of pathology co-
registered MR data sets. This work is presented in Chapter 4.
  
xxi 
 
Chapter 2 details the clinical characteristics of the patient cohort and the MP-
MRI acquisition methods and post processing used to generate the data used in 
chapters 3 and 4. Chapter 5 reports on a study where the r1 and r2* relaxivities of 
a common paramagnetic contrast agent are measured in blood and saline at 
both 3T and 7T.  This is important information to have when attempting to 
perform DCE-MRI studies as part of a MP-MRI protocol.  Previous studies done 
by Metzger et al. (4) have shown that, R2* effects of typical paramagnetic 
contrast agents make the determination of subject dependent arterial input 
functions impossible at 7T and results in an underestimation of pharmacokinetic 
parameters even if a model based function is used. Similar effects are expected 
to negatively impact other contrast enhanced studies when performed at 7T such 
as first pass perfusion and angiography exams relying on T1-weighted 
enhancement (5). Finally, Chapter 6 reports on some initial studies comparing 
MP-MRI with quantitative pathology while also highlighting future directions for 
the work contained in this thesis.  
1 
Chapter 1  Introduction 
1.1 Prostate Cancer 
According to the GLOBOCAN (Global Burden of Cancer Study) project, which 
provides contemporary estimates of the incidence, mortality and prevalence from 
major types of cancer at the national level, for 184 countries of the world, 
Prostate Cancer (PCa) was the second most common cancer among men 
worldwide (1) as of 2012. It is estimated that in 2014, 233,000 new cases of PCa 
will be diagnosed and 29,480 men will die of this disease in the United States 
alone(6). According to the American Cancer Society, 98.9% of men survive for 
five years or more after being diagnosed with all stages of PCa (local, regional or 
distant) (6). The increase of this 5-year survival percentage from 98.9 to 100% 
for men diagnosed with localized and regional PCa is attributed to early 
diagnosis of disease (7). 
1.2 Prostate Anatomy 
The prostate is a walnut-sized gland (Figure 1.1) located inferior to the bladder, 
superior to the penis and anterior to the rectum. A healthy prostate weighs 
around 20 to 25 grams, has a volume around 20 cc and measures around 3 cm x 
4cm x 2cm. The prostate consists of a base, an apex, anterior, posterior and two 
lateral surfaces and has the urine in the bladder run through its center via the 
urethra. The main function of the prostate is to produce a thin, milky fluid 
containing citric acid and acid phosphatase that is added to the seminal fluid at 
the time of ejaculation. Also seen in Figure 1.1 are the seminal vesicles, which 
are a pair of small tubular glands that are attached to the vas deferens (carrying-
away vessels) at the base of the bladder. The seminal vesicles produce fructose 
2 
that helps with the sperm motility. The fluid from the seminal vesicles makes up 
most of the volume of the ejaculatory fluid (8-13). 
Figure 1.1 shows the anatomy of the prostate in relation to other pelvic structures. Inset 
figure shows an enlarged view along with the base and apex. This image is provided 
courtesy of the National Cancer Institute website (http://www.cancer.gov). 
The prostate gland is divided into three distinct glandular regions each 
distinguishable from the other on the basis of histology, anatomical landmarks 
and susceptibility to pathologic disorders (14). These are the peripheral zone 
(PZ), which covers 70% of the prostate, central zone (25%), transition zone (TZ) 
(5%) and anterior Fibromuscular Stroma (5%). Figures 1.2 and 1.3 show these 
glandular zones in the form of a diagram and as seen on a T2-weighted MRI 
image respectively.  
Base 
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Figure 1.2 shows an axial view of the prostate showing zonal anatomy. The central 
gland (CG) as defined in this thesis (not shown in figure) is composed of everything 
other than PZ (i.e. TZ, CZ, Fibromuscular stroma). This image has been provided 
courtesy of SEER Prostate Cancer Training Module, U.S. National Institutes of Health, 
National Cancer Institute (http://training.seer.cancer.gov/). 
Figure 1.3 shows the zonal anatomy of the prostate as seen on a T2-weighted MRI.  The 
axial (a) and sagittal (b) images were obtained on a 3T Siemens Magnet using an 
endorectal coil (ERC). The center of the urethra is depicted by the yellow line.  
ERC 
ERC 
Bladder
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1.3 Cancer Diagnosis 
Adenocarcinomas (cancerous tumors) that arise from the glandular tissue make 
up 95% of PCa tumors. 75% of all PCa arises in the PZ, 20% in the TZ and about 
5-10% in the CZ while local extension of disease tends to be into capsule, 
bladder base and the seminal vesicles. PCa usually does not present any 
symptoms unless it reaches a very advanced stage. Most common local 
symptoms present themselves are urinary outflow obstruction and back pain 
(15). The serum PSA (Prostate Specific Antigen) level test, DRE (Digital Rectum 
Examination) and TRUS (Transrectal Ultrasound) guided biopsy are the three 
clinical examinations used for early diagnosis of PCa. A prostate biopsy is 
recommended to patients with an elevated PSA level (> 4 ng/mL) in their blood 
and a suspicious induration on DRE. TRUS guided biopsy is the current gold-
standard for prostate biopsies. While a prostate biopsy may be performed to 
confirm the presence of tumor at the location of a positive DRE and detect the 
cause of the elevated PSA, TRUS guided biopsies have shown low sensitivity 
(23-42%) (16,17).  
Biopsy results are graded with a Gleason Score (GS) which is based on 
the glandular pattern description of the tumor. The GS is a two part sum of the 
primary (predominant) and secondary (second most prevalent) grades, each on a 
scale of 1 (well differentiated) to 5 (least differentiated). Well-differentiated cancer 
cells resemble normal cells and are inclined to grow and spread at a slower rate 
than un-differentiated cancer cells that may lack normal tissue architecture 
(Figure 1.4). The GS score ranges from 2 to 10 and indicates the likeliness of a 
tumor to spread. A GS of 7 (3+4 or 4+3) is considered clinically significant with a 
worse prognosis than a GS of 6 (i.e. 3+3) (18-22).    
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Figure 1.4 Gleason Scale (image courtesy – Wikimedia.org). 
 
1.4 Multiparametric MRI in the detection of 
Prostate Cancer 
Among several diagnostic imaging modalities that are available for detection of 
PCa, Magnetic Resonance Imaging (MRI) occupies a unique position due to its 
excellent soft tissue contrast and its ability to generate tissue property dependent 
multi-parametric data (3). Conventional imaging techniques like CT have found 
limited use in PCa detection because of insufficient spatial and contrast 
resolution (23-25).  PET/CT is currently used for detection of post-treatment 
recurrence and has not shown conclusive detection capabilities for primary PCa 
diagnosis (26-28). MP-MRI is currently one of the most promising tools for PCa 
detection and staging with the potential to further impact disease management by 
characterizing disease aggressiveness and extent (12,29-34). MP-MRI refers to 
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the combination of multiple imaging methods and their associated quantitative 
maps such as T2 maps associated with T2-weighted imaging, ADC maps from 
diffusion weighted imaging (DWI), pharmacokinetic maps from dynamic contrast 
enhanced MRI (DCE-MRI) and metabolite ratio maps from three dimensional MR 
spectroscopic imaging (3D-MRSI). Quantitative MRI (qMR) parameters like T2, 
ADC, Ktrans, Kep, Ve, AUGC and those derived from MRS (Magnetic Resonance 
Spectroscopy) acquisitions have been shown to detect PCa and correlate with 
tumor grade (35-38). MP-MRI guided biopsy has shown good results in detecting 
significant disease and could reduce unnecessary biopsies (39,40). 
1.5 Multiparametric MRI based Predictive Models 
in the Detection of Prostate Cancer 
The ground truth in PCa detection is given by pathology. One way to achieve 
pathology comparable detection using MP-MRI is by the construction of a model 
that accurately predicts disease as defined on pathology. An MP-MRI model 
provides a standardized approach of combining multiple datasets for maximizing 
the predictive power of MP-MRI. A vast body of literature exists in the prediction 
of PCa using MP-MRI models and there are new studies being added every day 
(18-24). The process of assessing MP-MRI’s ability to predict what is currently 
only obtained through post prostatectomy pathology (PPP), involves correlating 
MP-MRI obtained in-vivo (inMR) with post-surgical specimens. This correlation 
with the pathologic Gold Standard involves the transfer of information obtained 
from pathology (i.e. grade and location of identified disease). This mapping has 
been accomplished through a variety of methods in the literature:  manual 
mapping of regions of interest (ROIs) (41); visual mapping of sextants (42) or 
octants (43,44); mapping locations of graded MR guided biopsy specimens (45) 
or calculated Gleason scores (43,46,47). The process of correlating manually 
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drawn regions of interest (ROIs) (41) on the MRI corresponding to identified 
areas of disease on pathology introduces potential biases of ROI drawing and 
placement used to generate predictive models. On the other hand using 
pathologically correlated slice sections (sextants (42), octants (43,44)) on MP-
MRI is prone to data averaging when a section contains a mix of cancer and non-
cancer tissue. These issues are addressed in this thesis (Chapter 4) where 
global anatomic features are used to guide a deformable registration method 
(LATIS) which is then used to map pathologist annotated regions of cancer 
directly to endorectal coil obtained in-vivo MRI images (48). The location size and 
extent are defined by global anatomic features. While an assumption is made 
about coincident slice locations and there is user interaction involved in defining 
internal structures for guiding the deformable registration methods, these are 
arguably less biased than other proposed methods. This image registration 
method is used to generate co-registered datasets which are then used in the 
development of MP-MRI based predictive models for the detection of PCa 
(Chapter 4).   
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Chapter 2 Materials and Methods 
2.1 Patient Population 
The patient cohort used in this thesis consisted of those who had biopsy 
confirmed PCa and were scheduled to undergo prostatectomy (46 men, age 
range 47 to 76 years with a median age of 63 years). All patients underwent 
imaging at the Center of Magnetic Resonance Research between November 
2009 and August 2012 after biopsy and before surgery after providing written 
consent under an Institutional Review Board approved protocol. The exclusion 
criteria included contraindications to endorectal coil placement including severe 
hemorrhoids, latex allergy, surgically absent rectum, severe inflammatory bowel 
disease; contraindications for MRI including ferromagnetic implants, history to 
shrapnel or shot gun injury, body mass index ≥ 40, cardiac pacemakers, 
claustrophobia, large tattoos, hip replacement and penile implants; 
contraindications to contrast agents including strong history of asthma and 
allergies, colostomy, kidney disease and Glomerular Filtration Rate (GFR)  < 30 
ml/min and prior treatment or procedures to treat PCa. Men received radical 
prostatectomy (RP) after an average gap of 27 days post MRI (range: 0-385 
days). The maximum gap of 385 days corresponds to a patient who was initially 
on active surveillance but underwent RP later. Quarter mounted histopathological 
sections were generated from the surgical prostate specimens. Table 2.1 shows 
the clinical characteristics summary of the patient population. 
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Table 2.1 Patient Population Clinical Characteristics 
2.2 MRI acquisition and Parametric Mapping 
2.2.1 Imaging Setup 
Patients were imaged on a 3T scanner (Siemens Healthcare, Erlangen 
Germany) transmitting with the whole body coil and receiving with a balloon-type 
endorectal coil (ERC) combined with an external surface array. The surface array 
consisted of two rows of 3 elements anteriorly from a flexible body coil and two 
rows of 3 elements posteriorly from a spine coil. The ERC was inserted after the 
patient assumed the left lateral decubitus position and inflated with 60 ml of 
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perfluorocarbon to reduce air induced susceptibility artifacts. Rotating back into 
the supine position, the anterior surface array was positioned with the coil 
centered at the level of the greater trochanter in the foot-head direction. In later 
studies, a urethral catheter (Bard, Latex radiopaque urethral catheter, Robinson 
model, 18Ch/ french-6.0mm) was inserted with the ERC to provide a pathway to 
release gas from the rectum which otherwise would build up behind the 
endorectal coil.  While not explicitly quantified, the use of the urethral catheter 
appeared to relieve the issue of gas in the bowel. In addition, it was inexpensive 
and did not affect study workflow or patient comfort as an endorectal coil was 
already being inserted. Other than instructing subjects to be nil per os (ingesting 
no fluids or solids) 4 hours prior to the study, no additional anti-peristaltic or 
preparation measures were taken. 
2.2.2 MRI Acquisitions Overview 
Scout images of the prostate in the sagittal, axial and coronal planes were 
acquired initially to check the depth and rotation of the ERC. After confirming the 
adequate positioning of the ERC, the rest of the MRI study proceeded and 
included the following acquisitions. 
1. Anatomic imaging using a T2-weighted (T2w) Turbo Spin Echo (T2-TSE)
sequence in the axial, sagittal and coronal planes.
2. Additional TSE datasets acquired in the axial plane at different echo times for
calculating T2 maps (T2-TSE).
3. T1-weighted Turbo Spin Echo (T1-TSE) imaging for the detection of post-
biopsy hemorrhage.
4. Multi Echo Spin Echo imaging as an alternative method for calculating T2
maps (T2-SEMC).
5. Single Shot Echo Planar Imaging (EPI) diffusion weighted imaging (DWI) for
calculation of Apparent Diffusion Coefficient (ADC) maps.
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6. 3D gradient echo data sets for calculating T1 maps using DESPOT1 (Driven 
Equilibrium Single Pulse Observation of T1). 
7. Dynamic Contrast Enhanced MRI (DCE-MRI) using 3D Flash VIBE (Volume 
Interpolated Breathold Examination (T1w3D-GRE). 
 
Acquisition parameters are tabulated in Table 2.2. All studies were run in the 
first-level control mode with prostate specific power and B0 adjustment. Further 
details for each acquisition and the calculation of parametric maps used for 
subsequent modeling are detailed below. 
 
 
 
  Table 2.2 MP-MRI study acquisition parameters 
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2.2.3 T2w Anatomic imaging 
Figure 2.1 T2-weighted image of the prostate. Hypointense region (arrow) indicates 
cancer. The units of the scale bar are in ms. 
T2-weighted (T2w) MRI is the traditional method of imaging the prostate and 
determining the location of PCa. On T2w sequences, in general, normal prostate 
PZ areas show high signal intensity owing to high water content whereas the CG 
areas (comprising of central and transition zones) show lower signal intensities. 
While PCa is frequently seen as a hypointense region in the PZ, some cancers 
are isointense and therefore cannot be seen on T2w images. T2w sequences 
show low specificity due to the high frequency of low intensity regions due to 
prostatitis, atrophy and calcifications (32). Hypointense regions can also be seen 
with areas of hemorrhage (post-biopsy or otherwise) infection and as a result of 
radiation or hormonal treatment. For this reason a gap of at least six to eight 
weeks post-biopsy is suggested prior to performing MRI. 
After confirming accurate endorectal coil placement, anatomic images 
were acquired using a T2-weighted (T2w) fast spin echo or Turbo Spin Echo (T2-
TSE) sequence in the transverse plane. The initial axial T2-TSE acquisition was 
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acquired with a left-right phase encoding and no parallel imaging acceleration. In 
cases where the predicted specific absorption rate (SAR) was too high, the 
repetition time (TR) of the transverse scan was increased accordingly resulting in 
a nominal repetition time of 6 s. All axial images were positioned such that the 
slice plane passed perpendicular to the posterior surface of the prostate. Coronal 
and sagittal T2w-TSE anatomic scans were acquired in orthogonal planes with 
respect to the transverse acquisitions with a TE of 107 ms and an acceleration 
factor of 2 with right-left and foot-head phase encoding directions, respectively. 
No SAR issues were present in these other orientations as fewer slices were 
acquired. 
2.2.4 T2 mapping 
Figure 2.2 T2-maps of the prostate using (a) T2-TSE (Turbo Spin Echo) (b) T2-SEMC 
(Spin Echo Multi Contrast) methods. Hypointense region (arrow) indicates area of 
cancer. The units of the scale bars are in ms.  
While T2w anatomic imaging provides the best anatomic detail of the prostate’s 
zonal anatomy and margins, there is evidence that there may be an advantage to 
calculating T2 maps (49,50). T2 mapping provides a measure of the apparent 
transverse relaxation time in milliseconds (ms) on a voxel by voxel basis. 
Measuring relaxation times instead of relying of image intensities as in T2w 
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imaging, is an ideal way to parameterize the anatomic images. The potential 
advantages result from the ability to use an absolute value for differentiating 
tissue and observing therapeutic effect.  When there is little normal tissue within 
a given image it becomes difficult to interpret abnormal regions based solely on 
signal intensity. Figure 2.2 shows two ways of achieving T2-maps of the prostate 
used in this research.  
The first method involved acquiring additional axial TSE data sets with 
echo times of 30, 74 and 144 ms. To accelerate acquisitions of these additional 
series, parallel imaging with an acceleration factor of 2 was used resulting in a 
scan time of 2:28s per series.  The mapping of T2 from these data was 
accomplished by methods previously described and validated by Liney et al. (51) 
and Gibbs et al.(52). Transverse relaxation rates were calculated through a semi-
logarithmic linear least squares fit to the signal intensity equation,  
 S = S0e
-TE
T2 (2.1) 
where S0 represents the signal at TE=0 ms (the proton density signal) and S is 
the signal intensity at a given TE from the multiple TSE datasets acquired at 
different echo times. The function LINFIT in IDL (ITT Boulder, CO) was used to 
compute this value. The T2-TSE mapping approach was chosen due to its 
acquisition and hence anatomical similarity to the T2-weighted acquisition. This is 
especially important during the transfer of pathology registered tumor regions 
from the T2-weighted image to the T2 map. The T2-TSE approach is also more 
time-efficient compared to the multiecho approach and as a result is less prone 
to motion artifacts. 
As an alternative to the T2 maps generated by the multiple TSE 
acquisitions described above, a spin echo multi-contrast (SEMC) acquisition was 
also obtained. In this type of sequence, the echoes of the spin echo train each 
contribute to a different image with varying T2-weighting. A total of 11 echoes 
were acquired thus giving rise to 11 images with echo times ranging from 13.3 to 
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154.1 ms. The disadvantage of this acquisition compared to the multiple TSE 
imaging series for generating T2 maps was a decrease in resolution and increase 
in scan time while the advantage was the freedom from motion artifacts between 
images of each echo time and the availability of more datasets for T2 
quantification. Because of the presence of more points along the T2 decay curve, 
a non-linear fit using the function CURVEFIT in IDL was used. It was important to 
remove the image generated from the first echo of the series as this first point 
exhibited non-monoexponential characteristics. The signal of the first point is a 
pure echo whereas signals acquired at subsequent TEs are composed of primary 
and stimulated echoes as the refocusing pulse flip angles are not exactly 180˚ 
due to B1 field inhomogeneities. This first point was not included as it would have 
led to an overestimation of T2 (53).  
2.2.5 T1-weighted imaging and mapping 
Figure 2.3 (a) T1-weighted image and T1 map (DESPOT1) (54) of the prostate. The units 
of the scale bars in are SI units (a) and ms (b).  
In this work, a T1-weighted Turbo Spin Echo (T1-TSE) sequence was used 
for the qualitative assessment of post-biopsy hemorrhage. While an effective 
means to avoid misreading the associated T2-weighted images, the use of the 
qualitative T1-weighted images, especially in the presence of an uncorrected 
sensitivity profile of the endorectal coil, are not reliable for use in the multi-
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parametric model development, therefore the generation of T1 maps was 
desired. T1 maps were generated using the 3D DESPOT1 (Driven Equilibrium 
Single Pulse Observation of T1) method (54). The data acquired was the same 
used for the DCE-MRI studies detailed below but with 4 averages and varying flip 
angles of 2, 5 10 and 12 degrees. In DESPOT1, the T1 is calculated by fitting the 
signal intensities obtained from the multiple flip angle images using the LINFIT 
function in IDL (ITT Boulder, CO). 
2.2.6 Maps of Apparent Diffusion Coefficient (ADC) 
Figure 2.4  Apparent Diffusion Coefficient (ADC) map of the prostate. This image was 
obtained with a diffusion weights (b) of 50, 400 and 800 s/mm2. Hypointense region 
(arrow) is indicative of restricted diffusion (cancer). Units of scale bar are in 10-6 mm2s-1. 
Diffusion Weighted Imaging (DWI) sequences are useful in measuring the 
restriction of diffusion in biological tissues and properties such as cellular density, 
membrane permeability and space between cells and thus can aid in 
distinguishing benign from malignant tissues. They have the combined 
advantages of short acquisition times and low technical demand for image post-
processing in comparison to DCE and MRS acquisitions. DWI images are 
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generally post-processed to obtain Apparent Diffusion Coefficient (ADC) maps 
(55) which are used to characterize the Brownian motion of water primarily from 
the extracellular and fluid filled compartments in tissue (56). Diffusion is more 
restricted in conditions of high cellular density. Tumor ADC values have been 
shown to be significantly lower than those found in normal prostate gland (57) 
due to the denser packing of cells and the loss of the normal ductal architecture 
in the prostate.  
ADC maps were generated from single shot EPI acquisitions with different 
diffusion weights characterized by their b values of 50, 400 and 800 s/mm2. 
These b values were chosen as there is historical precedence with the 
advantage of reducing the confounding effects of perfusion by avoiding b = 0 
s/mm2 (58,59) and the promise of adequate SNR by restricting the upper b-value 
to 800 s/mm2. ADC was calculated by linear fitting the data using the equation,  
 S(b) = S0e-b∙ADC (2.2) 
where the ADC is determined by finding the slope of the line fit to the natural log 
of the DWI signal intensities versus b-values. The ADC map was generated in 
the Siemens Trio Platform using the “3-Scan Trace” method. 
2.2.7 Dynamic Contrast Enhanced (DCE) Imaging 
The Dynamic Contrast Enhanced MRI (DCE-MRI) protocol involves the 
acquisition of images before and after the intravenous injection of the exogenous 
contrast agent. DCE-MRI provides information about neo-angiogenesis where 
cancer is typically found to have a faster uptake and higher permeability than 
healthy tissues (22). Angiogenesis is known to lead to varying combinations of 
increased blood flow, microvascular density and capillary leakiness in malignant 
lesions. Quantitative interpretation of DCE-MRI data, involves first converting the 
acquired dynamic signal intensity curves obtained during the typical dynamic 
acquisition into the gadolinium concentration curves. This method of assessing 
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microvascular changes in tumors employs pharmacokinetic models to determine 
the rate of exchange of contrast between plasma and the extravascular, 
extracellular space and allows specific quantitative vascular parameters, such as 
Ktrans, Kep, Ve and AUGC can be estimated. 
Ktrans (transfer constant) describes the diffusion of contrast agent from the 
intravascular space to the extravascular (interstitial) space and depends on the 
flow rate per unit volume, the permeability and the surface area of the tissue 
capillaries. This can be characterized by the wash-in of contrast to the tissue. Kep 
(rate constant) represents the leakage of contrast from the extravascular space 
to the blood plasma. Ve is an estimate of the extravascular extracellular volume 
also referred as the EES or interstitial space. AUGC stands for the Area Under 
the Gadolinium concentration curve (22). All of these parameters have been 
shown to be elevated in tumors. This quantitative approach has also been 
proposed to be more reproducible, enabling serial measurements of perfusion 
parameters over time to facilitate evaluation of treatment response (60). Figure 
2.5 shows the DCE-MRI maps for a prostate with tumor in right peripheral zone. 
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Figure 2.5 DCE-MRI maps of the prostate. Units of the scale bar are 10-3 × min-1 (Ktrans), 
10-3 × min-1(Kep) and 10-3 (Ve). Increased Ktrans (wash-in), Kep (wash-out) and AUGC (Area 
Under Gadolinium Concentration Curve) identifies area of cancer in these maps. 
The DCE-MRI data were acquired with a 3D T1-weighted gradient echo 
acquisition (i.e. 3D VIBE - Volume Interpolated Breathold Examination in the 
manufacturers’ lexicon). This sequence is referred to as T1w3D-GRE in Table 
2.2. In summary, the acquisition has a temporal resolution of 6 s and spatial 
resolution of 1x1x4 mm3. A total of 50 dynamics were acquired for a total 
acquisition time of 5 min. In the case that the calculated power deposition was 
too high for the acquisition, a slightly lower flip angle was prescribed until the 
sequence could run. Pharmacokinetic maps were generated by using a modified 
Tofts model (61) with a population averaged arterial input function (AIF) (62). The 
10-3min-1 10-3min-1 
10-3
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fitted model provided the following pharmacokinetic parameters: Ktrans (Forward 
Volume Transfer Constant, min-1), Kep (Reflux Rate between the Extracellular 
Space and the Plasma, min-1), Ve (Fractional Extravascular Extracellular Space, 
Ve = Ktrans/Kep) and AUGC (Area Under Gadolinium Curve). All analyses were 
carried out in IDL (ITT Boulder, CO) (63-65). 
2.3 Histopathology 
2.3.1 Surgical to Pathology Workflow 
After removal from the patient, the prostate is fixed with formalin and then gross 
sectioned to match, as close as possible, the MR imaging planes. For this 
purpose, a special sectioning box (Figure 2.6) was constructed and a sectioning 
protocol established (Figure 2.7 a, b).  After amputation of the seminal vesicles 
and vasa deferentia at the base and shaving off 1mm of the proximal urethral 
margin, the prostate was placed in the sectioning box so that the posterior 
surface of the prostate was approximately parallel to the bottom and the long axis 
of the box.  Vertical slits in the box, 3 mm apart, allowed the consistent parallel 
sections to be cut perpendicular to the posterior surface of the prostate with a 
thickness of 3 mm to match the orientation and thickness of the axial MRI slices.   
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Figure 2.6 Prostate sectioning box made of Acrylic and Teflon. The box is shown with a 
spherical prostate model and the movable walls on the left (WL) right (WR) and base 
(WB) are pushed in to hold the model securely. Each moveable wall is held in place with 
a locking screws SL, SR and SB, respectively. A standard pathology blade is inserted 
through the milled slits in the acrylic pieces that make up the left and right walls. Each 
successive axial cut through the prostate requires passing through the next slit in the 
side walls. The tolerance is such that the blade can only traverse through the 
corresponding slit on the opposite side. 
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Figure 2.7 Diagrams of pathologic sectioning protocol overlaid on a coronal (a) and axial 
(b) T2w image. After placing the prostate in the sectioning box, the first cut made is 
approximately 0.6 mm from the apex of the gland to create the apical section, with 
successive axial cuts 3mm apart moving towards the base. The axial cross-sections are 
designated by letters “A”, “B”, “C”, etc., depending on the size of the prostate, with “A” 
being the most apical slice.  Slices are divided into four quarters (b). Each quarter is 
labeled based on the letter of the slice from which it comes and its position in the slice 
(e.g. anterior/posterior = A/P and right/left = R/L). After removal from the box, the apical 
portion is sectioned in 2mm intervals with parallel cuts emanating from the urethra.  The 
sections near the urethra are labeled “RDUMA” (right distal urethral margin A) and 
“LDUMA” (left distal urethral margin A). The next two sections from the center are then 
labeled “RDUMB” and “LDUMB”, etc. This process continues out to the lateral margins 
of the apical section. Each slice section is then embedded in a paraffin block and one 4-
micrometer H&E-stained slide is prepared from each section and digitized. A pathologist 
then digitally annotates the prostate capsule (red contour) and cancer regions (brown 
contour) on each slide. 
2.3.2 Digitization 
Gross sectioned prostates were subjected to quarter mount histological section 
(QMHS) pathologic processing. Sections were paraffin embedded, Hematoxylin 
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and Eosin (H&E) stained, and cut at 4 μm thickness. H&E stained slides were 
digitized using a whole slide scanner (ScanScope CS, Aperio, Vista, CA). 
2.3.3 Annotation 
The prostate pseudo-capsule and tumor regions within the digitized sections 
were annotated by a board certified pathologist with 15 years’ experience, at 20X 
magnification (resolution 0.58μm per pixel) using a pen tablet screen (Cintiq 
21UX, Wacom, Kazo-shi, Saitama, Japan). 
2.3.4 Data Assembly 
Digitally annotated QMHS slides were then manually assembled into PWM by 
aligning the capsule annotations of the quartered pathology sections to form a 
continuous capsule while minimizing overlap of tissues between the combined 
sections.  Anatomic features in the pathology sections being assembled also 
aided in aligning the QMHS images (Figure 2.8 a, b).   
Figure 2.8 (a) Slides from a complete axial slice are then manually assembled into a 
PWM by aligning the capsule annotations of the quartered pathology sections to form a 
continuous capsule while minimizing the overlap of tissues between the combined 
sections (b). 
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Chapter 3 LATIS Registration 
This chapter is adapted with permission from the following publication: 
Kalavagunta, C., Zhou, X., Schmechel, S. C. and Metzger, G. J. (2014), 
Registration of in vivo prostate MRI and pseudo-whole mount histology using 
Local Affine Transformations guided by Internal Structures (LATIS). J. Magn. 
Reson. Imaging. doi: 10.1002/jmri.24629 
This was a collaborative project between Dr Greg Metzger, Dr. Xiangmin Zhou, 
Dr. Stephen Schmechel and me. My primary role in this project was the 
development of the Matlab software tools to obtain the necessary inputs for the 
registration process, perform the registration procedures, visualize the results, 
validate registration performance and enable the application of all registration 
results to pathologist annotated cancer regions. Implementation of these 
procedures and validation was a critical component of the MP-MRI model 
generation process discussed in Chapter 4. 
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3.1 Synopsis 
A novel registration approach called LATIS (Local Affine Transformation assisted 
by Internal Structures) for co-registering post prostatectomy pseudo-whole mount 
(PWM) pathological sections with in vivo MRI (Magnetic Resonance Imaging) 
images is presented. This study included thirty-five patients with biopsy-proven 
PCa that were imaged at 3T with an endorectal coil. Excised prostate specimens 
underwent quarter mount step-section pathologic processing, digitization, 
annotation and assembly into a PWM. Manually annotated macro-structures on 
both pathology and MRI were used to assist registration using a relaxed local 
affine transformation approximation. Registration accuracy was assessed by 
calculation of the dice similarity coefficient (DSC) between transformed and 
target capsule masks and least square distance between transformed and target 
landmark positions. LATIS registration resulted in a DSC value of 0.991±0.004 
and registration accuracy of 1.54±0.64 mm based on identified landmarks 
common to both datasets. Image registration performed without the use of 
internal structures led to an 87% increase in landmark based registration error. 
Derived transformation matrices were used to map regions of pathologically 
defined disease to MRI.LATIS was used to successfully co-register digital 
pathology with in vivo MRI to facilitate improved correlative studies between 
pathologically identified features of PCa and MP-MRI.  
3.2 Introduction 
Multi-parametric maps of anatomic, vascular and metabolic data of the prostate 
acquired using MP-MRI can yield improved discrimination of the extent and 
aggressiveness of PCa (66-68). An important step in developing and validating 
MP-MRI biomarkers to detect the extent and aggressiveness of PCa is the 
registration of in vivo MR images with histopathological sections obtained from 
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prostatectomy. This multi-modal registration would enable correlation of MRI with 
postoperative histopathological determination of extent and tumor grade, and 
ultimately the molecular assessment of aggressiveness.  
There has been much interest in the multi-modal co-registration of 
prostate MRI with other imaging modalities such as CT for treatment planning 
(69-72), ultrasound for guiding biopsies (73), and pathology for validation of 
cancer detection (74). With each combination of source and target data come 
unique challenges for the registration procedure.  In this work, the goal was to 
register in vivo MRI data obtained with a balloon-type endorectal coil (ERCinMR) 
with images of pseudo-whole mounts (PWM) constructed from quarter mount 
histologic sections.  
The prostate images from in vivo MRI and pathology possess different 
amounts of deformation/distortion with respect to each other.  For example, after 
digitally assembling quarter mount histological sections into a PWM, the resulting 
PWM is different from a true whole mount image in multiple ways, including: (a) 
the boundary shape of the prostate, (b) the unfilled space or gaps between the 
quarter mount histological sections, and (c) deformation/distortion of each 
individual quarter. Additionally, the difference between the ERCinMR and the 
tissue observed on pathology is a result of multiple factors, including:  (a) 
physical distortion of the prostate due to the presence of the inflated endorectal 
coil, (b) deformation of the tissue after excision and (c) shrinking of the tissue due 
to fixation. Without completely characterizing all the intermediate deformations, 
the registration procedure described in this work focuses on directly registering 
ERCinMR with PWM images due to the fact that both data sets are readily 
available, and characterization of the intermediate deformations are not easily 
obtainable. 
 LATIS is a technique that uses a relaxed Local Affine Transformation 
approximation assisted by the identification of large Internal Structures. In LATIS, 
the prostate capsule and large internal anatomic structures are used as 
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constraints for registration. This technique does not require the accurate 
definition of a set of multiple paired landmarks between the source and target 
data which are difficult to obtain in general and the basis for leading registration 
methods tackling similar problems. The large structures are, arguably, easier to 
manually identify on both pathology and MRI and provide a larger continuum of 
spatial information to guide the registration procedure. In this study, the ability of 
LATIS to co-register PWM and ERCinMR images is evaluated, and the use of 
this registration to map regions of pathologically identified cancer onto the in vivo 
MRI is demonstrated.   
3.3 Methods 
Data used in this study was obtained from patients with biopsy-proven prostate 
cancer (35 men, age range 50-73 years, mean age 62 years) after obtaining 
written signed consent for a study reviewed and approved by the local 
Institutional Review Board.  
3.3.1 In Vivo MR Data 
In vivo MR data was obtained from the T2-weighted (T2w) axial MR images. The 
axial images were positioned such that the slice plane passed perpendicular to 
the posterior surface of the prostate (See Chapter 2 Sections 2.2.1 to 2.2.3). 
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Figure 3.1 A schematic demonstrating the procedure to co-register pathology to T2w 
MRI using LATIS. First, the source (a) and target (b) images are segmented, scaled and 
translated. Second, the prostate capsule and internal structure masks are identified to 
constrain the pathology transformation. The source and target masks (d and e) are 
registered and a transformation matrix ?is obtained. Images (c) and (d) show the 
transformation flow matrix and applied deformation field respectively. Third, the 
transformation matrix ?is applied (red arrow) to the pathology (f) which places it in spatial 
correspondence to the T2w MRI resulting in (g).Lastly, applying the transformation matrix 
?to each one of the annotated cancer regions (i) places them in the spatial framework of 
the anatomic T2w images (j).  
3.3.2 Pathology Data 
Excised prostates were formalin fixed, gross sectioned, paraffin embedded, cut 
at 3 μm, H&E  stained, digitized, annotated by  an  experienced  pathologist and 
assembled into a PWM. The sectioning protocol is shown in Figure 2.7 a and b. 
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based on a special sectioning box (Figure 2.6). Vertical slits in the box, 3 mm 
apart, allowed the consistent parallel sections to be cut perpendicular to the 
posterior surface of the prostate with a thickness of 3 mm to match the 
orientation and thickness of the axial ERCinMR slices. Positioning both the 
imaging and sectioning planes perpendicular to the posterior surface of the 
prostate was the method we used to get slices which matched as closely as 
possible. From the assembled PWM, binary masks of both annotated tumor 
regions and the prostate capsule were generated (Figure 3.1). For each patient, 
a single PWM at the center of the index lesion was chosen for registration 
(Chapter 2 Section 2.3). 
3.3.3 Image Registration 
In order to register the PWM (source image) to the ERCinMR (target image) 
(Figure 3.1), a transformation that can map the source image to the target image 
must be found. Since the source and target image belong to two completely 
different imaging modalities, a direct mapping relationship between these two 
images cannot be readily established without additional inputs or modifications. 
The first step in the process involved manually converting the source and target 
into tri-intensity grayscale images (Figure 3.1) such that the internal structures 
had a grayscale value of 128 and the rest of the prostate has a value of 255. This 
created the potential for developing a direct mapping between the two datasets. 
To register the two tri-intensity grayscale images, some assumptions are 
introduced:  
1. The 2-dimensional source and target images correspond to the same
cross-section of the prostate in terms of the position and the outward
normal direction.
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2. There exists a path-independent, unique mapping between the source and
the target image.
3. The image intensity between the source and target image is conserved.
These three assumptions are reasonable and can be easily satisfied in 
most cases. The first assumption is met by the standard data collection and 
sectioning protocols employed in this study. This condition is of the upmost 
importance because, as the source and target images diverge in terms of their 
spatial correspondence, there is decreasing benefit to perform the registration 
since the cancer region annotated in the source image cannot be guaranteed to 
exist in the target image. 
The second assumption establishes that the problem is well-posed. 
Supposing assumption No.1 holds, there exists a mapping relation between the 
source and target images as they both represent different realizations of the 
same cross-section of the prostate. Employing a linear approximation for the 
mapping will guarantee a unique and path-independent solution. The existence 
of a solution and its uniqueness establish that the problem is well-posed (75), 
hence the solution is guaranteed. 
The third assumption forms the basis for the image registration procedure. 
With assumption No. 1, both the source and the target images are referring to the 
same cross-section of the prostate but differ due to in-plane deformation. After 
converting the source and target images to the tri-grayscale-images, the intensity 
conservation principle (76) is readily applicable and a relationship can be 
established between the source and target images. With this established 
relationship, the mapping relation between the source and target image can 
subsequently be derived with the help of assumption No. 2. The derivation is 
shown in next section. In summary, although three assumptions were introduced, 
assumption No. 1 is the most fundamental. If assumption No. 1 is achievable, 
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assumptions No. 2 and 3 are imposed, both of which serve as a foundation for 
the following registration derivation.   
3.3.4 Theory 
Let I(x, y, t) be the intensity of an image, which is a function of space and time. 
When the source and the target tri-grayscale-images are treated as the images 
of a deforming prostate at two different time points, time is involved. Therefore, 
one can assign the source image at t1 and assign the target image at t2.  
Following assumption No.1, assumption No. 3 imposes the intensity conservation 
principle which implies that the total derivative of the intensity is invariant, i.e. 
????? ?? ??
?? ? ?? 
(3.1) 
Expanding the left hand side (LHS) of the equation, it becomes 
????? ?? ??
?? ?
????? ?? ??
??
??
?? ?
????? ?? ??
??
??
?? ?
????? ?? ??
??
? ????? ? ????? ? ??? ? ??? 
(3.2) 
According to assumption No. 2, there exists a transformation such that the 
above equation (3.2) is satisfied. Since this exact transformation is unknown, the 
assumption of a local affine transformation is made between the source and 
target image, which is, 
?
?
??
?
? ? ?
??? ? ??? ? ??
? ??? ? ??? ? ??
? ??????? ?
? ?
?
?
?
? 
(3.3) 
where ??? ?? represents the source image at t1, ??? ??? represents the target image 
at t2, ???? ??? is the translation, and ? is the rotational angle. And since the local 
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affine transformation is a proposed approximation, a more relaxed linear 
approximation can be adopted, namely, 
?
?
??
?
? ? ?
?? ?? ???? ?? ??
? ? ?
? ?
?
?
?
? 
(3.4) 
which relaxes the ? constraint between the transformation parameters 
???? ??? ??? ??? ???. This linear approximation satisfies assumption No. 2. With 
respect to the approximation, there is no qualitative difference between equation 
(3.3) and equation (3.1) since they are both linear functions but, as shown in a 
later part of this section, it is desirable to select equation (3.1) over equation (3.3) 
to reduce the correlation between the transformation parameters resulting in a 
simpler solution procedure.  Substituting equation (3.1) into equation (3.2) leads 
to the LHS not being equal to zero because equation (3.1) is an approximation 
and an approximations result in errors. Therefore, locally, we have an error 
function in terms of ??? ??? where????, ???, and ??? are functions of ??? ???, which  states 
that 
????? ??? ??? ??? ??? ??? ? ? ????? ? ?????? ? ??? (3.5) 
Now the objective of the registration process is to find a set of transformation 
parameters ?? ? ???? ??? ??? ??? ??? ???? such that error function e is equal to or is 
minimal with respect to zero. In order to seek the solution for the transformation 
parameters, a quadric error functional is constructed as  
? ? ?? ?
??? (3.6) 
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Further taking the variation of the quadratic functional, yields, 
?? ? ????? ??? ?
??
???? ???? ? ????????????????????
(3.7) 
Since the transformation parameters are constants, the higher order terms 
vanish after taking the first variation of the  quadratic functional, i.e. ??? ? ?, for all 
i > 1. And according to the Ekeland’s variational principle (77), there exist a 
solution for ?? such that ?? ? ? which corresponding to the minimization of the 
error function e. Since ???  is arbitrary and is not always equal to zero, the only 
possibility to yield ?? ? ? is that the following equation is always satisfied, 
??? ? ????? ?
???
??? ? ? ?????
??? ? ???????? ? ?? (3.8) 
Where 
??? ? ??????????????????????????????????????? (3.9) 
? ? ???? ? ????? ? ??? (3.10) 
Therefore, the transformation parameters can be solved from the following 
equation 
??????? ? ???? (3.11) 
where the resulting transformation parameters are the optimal solution satisfying 
equation (3.2) and subsequently, provides the transformation satisfying equation 
(3.1).  
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A pixel by pixel solution of the transformation parameters is 
computationally expensive and may be ill-posed in the sense of Hadamard(75). 
For reducing the computational cost, the transformation parameters can be 
solved weakly, i.e., for a neighborhood of n by n pixels,  
?
??
?
? ?????
?
???
???
??????? ?
??
?
?
??
?
? ?????
?
???
???
??????? ?
??
?
?? ?
?
??
?
? ???
?
???
???
??????? ?
??
?
(3.12) 
where ? represents the domain of the image and i and j are referring to the index 
of the pixels in the x and y directions, respectively. The image is broken up into a 
grid of these neighborhoods such that the larger the neighborhood, the coarser 
the grid. However, due to the properties of the tri-intensity grayscale images, 
equation (3.12) is ill-posed (non-invertible). This is because for the entire 
neighborhood of n by n pixels located within the same intensity grayscale region, 
we have 
??? ? ??? ? ??? ? ? (3.13) 
and,  
????? ? ??? ?? ? ? (3.14) 
In order to achieve a solution for equation (3.12), the matrix of the left hand side 
needs to be diagonally dominant. Thus, the following modifications can be made 
in equation (3.11) to add a diagonal matrix on both the left hand side and right 
hand side: 
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????? ???? ? ???? ? ?? ? ??? (3.15) 
where ? is a diagonal constant matrix with a reasonably large positive number for 
the diagonal elements and zeroes for the off-diagonals. Based on our 
experience, a ?kk=1010 is chosen. Since the same quantities are added equally 
on both side of the equation, it does not change or affect the solution of the 
original equation but makes it always solvable. Thus equation (3.11) becomes 
??? ? ????? ???? ? ??????? ? ???? (3.16) 
The fixed-point iteration method can now be readily employed for solving 
equation (3.16). Employing the fixed-point iteration method (49), ?? can be solved 
iteratively from 
??????? ? ????? ???? ? ??????? ? ??????? (3.17) 
with an initial guess of ????? ? ? when m=0 for the initial step. ` 
3.3.5 Multi-Resolution Optimization 
Two principle causes of potentially large deformations in local regions of the 
prostate between the PWM and ERCinMR images result from the sectioning and 
reassembly of the pathology specimens and the use of an ERC. The optimal 
neighborhood size, n x n, over which ?? needs to be solved is unknown. For 
neighborhoods too large, the accuracy of the registration would be insufficient, 
and for neighborhoods to small, the registration method would be ill-posed in the 
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sense of Hadamard (75). Therefore, instead of choosing a fixed neighborhood 
size, a multi-resolution optimization strategy is employed. 
The idea behind the method of multi-resolution optimization for registration 
is that the starting grid of neighborhoods covering the image is small (low 
resolution) while as the optimization progresses the resolution of the grid 
increases (i.e. decreasing neighborhood size).  The solution in each step in the 
progression of the grid refinement provides an improved initial guess for the 
subsequent higher resolution grid. In the course of registering PWM to the 
ERCinMR image, a sequence of 2n grids are used, where n is equal to 0, 1, 2 ... 
etc. The final transformation is the accumulated transformation of the multiple 
steps with the criteria to stop the refinement of the grid mesh being when the L2-
norm of the displacement between step n and step n+1 is less than 0.1 pixels. 
3.3.6 Registration Procedure 
The image registration workflow for a sample case is shown in the Figure 3.1. 
After choosing the assembled pathology PWM slice, the corresponding target 
T2w ERCinMR slice was identified by choosing a slice at the same approximate 
position from the apex and verifying the existence of similar anatomic features. 
The source (PWM) is shown in Figure 3.1.1a. The target (ERCinMR, T2w) is 
shown in Figure 3.1.1b. The prostate region in the ERCinMR image was 
extracted masking with capsule contours drawn in a semi-automated 
segmentation program (Segasist, Ontario, Canada) by an experienced prostate 
MRI researcher (GJM). The PWM images were also masked by the combined 
capsule annotations defined by the study pathologist (SCS).  The masked 
ERCinMR image was upsampled to 512×512, to match the matrix size of the 
PWM, and translated to achieve a greater than 50% overlap with the masked 
PWM.  New annotation regions defining the easily identifiable large internal 
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structures for the PWM data were generated while simultaneously annotating 
similar structures on the ERCinMR. These internal structures were defined by a 
number of identifiable features including the central gland-peripheral zone 
boundary, transition zone, apex-semicircular sphincter and bilateral nodules of 
benign prostatic hypertrophy.  These images were converted into tri-intensity 
(White = 255, Black = 0, Gray = 128) grayscale source and target images 
(Figures 3.2a and 3.2b) where the white regions delineate the internal structures. 
Using the pre-defined controls (large internal structures and prostate boundary) 
found in the source and target, LATIS was used to register the two images. The 
local affine transformation component of the registration procedure was adapted 
from methods originally published by Periaswamy and Farid (78-80). The 
application of the final transformation matrix to the masked grayscale PWM 
image (Figure 3.1.3a) and the resulting warped source image (Figure 3.1.3b) is 
shown.  The application of the final transformation matrix warping the tumor 
region masks from the PWM to the ERCinMR can be seen in Figures 3.1.4 a and 
b. Other than where specifically stated, the registration steps and the
visualization of results were performed in Matlab (MathWorks, MA, USA) running 
on a Windows 2.80 GHz Intel i5 CPU machine with 12 GB RAM. 
3.3.7 Analysis 
Two metrics were used to evaluate the accuracy of the registration methods. The 
first method was the Dice similarity coefficient (DSC) which measures the overlap 
between the target and registered source. The DSC for two images A and B is 
defined as the intersection of the two images divided by the mean sum of the 
images 
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Dice Similarity Coefficient = 
? ? ?? ? ??
??? ? ???
(3.18) 
The second validation method involved identifying identical landmarks by visual 
inspection on both the native PWM and ERCinMR images. The process of 
identifying landmarks was independently performed by two experienced prostate 
researchers with four (CK) and eleven years (GJM) experience. The landmarks 
selected were also done so independently from the large internal structures used 
for registration. Landmark positions on the PWM were masked using circular 
ROIs (radius, 8 pixels, pixel size = 0.54 mm) to give a feature marked PWM 
(fmPWM) image. A circular area of this magnitude was chosen to easily identify 
the feature in the downscaled registered source. The transformation matrix, 
obtained earlier for this case, was applied to the fmPWM image and transformed 
pixel positions were obtained from the registered fmPWM image. Target 
registration error (TRE) in mm was calculated using the root mean squared 
distance between the transformed pixel positions from the fmPWM and the target 
pixel position on the ERCinMR. For the thirty five cases, landmarks for the 
registration accuracy calculation were drawn and a total of 103 such landmarks 
were identified by the two observers for error analysis.  To ascertain the impact 
of the internal structures as a guide for image registration, these thirty five cases 
were again registered without using internal structures and the registration 
accuracy assessed. The source and target images in this case were the masked 
PWM and ERCinMR capsule masks.  
3.3.8 Statistical Analysis 
The average TRE and DSC are reported as the mean ± standard deviation and 
were calculated using Matlab (MathWorks, MA, USA). A p-value <0.005 was 
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considered statistically significant when evaluating the difference in registration 
accuracy with and without the use of internal structures. The p-value analysis 
was performed in OriginLab 9.0 (Origin Lab Corporation, USA).  
3.4 Results 
Five representative cases are provided in Figure 3.2. The assembled PWM 
images are shown with the annotated tumor regions and cropped to the capsule 
borders by using the combined capsule annotations created by the study 
pathologist. LATIS was used to register the PWM data to the ERCinMR. The 
transformation? was then used to warp all annotated cancer regions from the 
assembled pathology to MRI (Figure 3.2 Column b).  The registration calculation 
per case took on the order of 11 minutes. 
The mean DSC after registration was 0.991±0.004 which represents 
nearly total correspondence by this metric after registration. The mean, minimum, 
maximum and standard deviation of the registration error based on the landmark 
method are given in Table 3.1. The average overall registration error was 
1.54±0.64 mm when using internal structures and 2.92±1.76 mm without internal 
structures, a statistically significant increase in registration error of 87% in the 
absence of additional information to guide registration (p < 0.0001). An example 
of the landmark registration accuracy assessment is shown in Figure 3.3. 
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Figure 3.2 Registration results. Column ‘a’ shows the masked PWM with annotated 
tumor regions. Column ‘b’ shows the registered tumor regions overlaid on the ERCinMR. 
Column ‘c’ shows the original ERCinMR. 
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Figure 3.3  Registration accuracy metric calculation workflow - (a) Feature marked 
masked PWM. (b) Corresponding features on ERCinMR. (c) Warped feature embedded 
masked PWM. (d) Feature embedded masked ERCinMR. 
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Table 3.1 Multi–user registration accuracy metric statistics 
3.5 Discussion 
A registration approach using a relaxed local affine transformation approximation, 
assisted by large internal structures as constraints to improve registration 
accuracy, has been  presented for co-registering post prostatectomy pseudo-
whole mount pathological sections with T2-weighted in vivo MRI images obtained 
with an ERC. In this study, slides made from quarter mount histologic sections 
were used to generate the PWM images as the ability to section, store and 
digitize whole mount data does not exist at our institution. Many institutions find 
themselves with similar limitations in terms of processing the excised prostate, 
therefore the methods presented here are very relevant for MRI studies wanting 
to use correlative pathology for identifying and validating MRI biomarkers for 
prostate cancer detection and grading.  
3.5.1 Registration Methods 
The registration between prostate histopathology and MRI images belongs to the 
category of multi-modal registration. Previous work in this area has investigated 
registering whole mount pathology (WM) to in vivo MRI  (inMR) acquired without 
an ERC (74), in vivo MRI  acquired with an ERC (ERCinMR) (81-86) and ex vivo 
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MRI (exMR, paraformaldehyde fixed prostatectomy specimen)  (86-88). While 
less prevalent in the literature, registration with PWM pathology has also been 
performed with exMR (81,89-91), inMR acquired without an ERC and inMR (85) 
acquired with an ERC (92).  
Two dominant approaches exist in published literature addressing the 
registration of pathology to MRI; the thin plate spline (TPS)-based (74,81,83-
86,89,90,93) and B-spline (BSp)-based (87,94,95) methods. The TPS approach 
utilizes pre-defined control point pairs identified from different images to warp the 
source image to the target image using a multidimensional interpolation method 
(93). The result of the TPS-based methods is highly dependent on the manual 
selection of the control point pairs, which requires knowledge of the control point 
locations and distributions in both images. Such information may not be readily 
available in all the cases within the ERCinMR and PWM images.  Also, since 
each pair of control points in the TPS method influences the entire image, this 
method assumes continuous source and target images, smooth deformation and 
distribution of control points over the entire image. Such assumptions are not 
valid for the PWM images used in this study. 
In contrast to the TPS-based approach, the influence of the control points 
for the BSp-based approach is localized especially when it is combined with free 
form deformation (FFD) (94). With the FFD BSp approach, each control point is 
predominately influenced by the neighboring grid tiles. This feature makes it 
suitable for registering the WM to both exMR and inMR images as well as the 
WM to the ERCinMR images. The BSp approach however, provides a smooth 
and continuous deformation field and thus is far from ideal for directly registering 
PWM to ERCinMR.  
Some studies have used mutual information (MI) as an alignment 
measure (82,91,92,96-100). MI has been specifically designed to address 
registration of multi-modal data (100) and is based on information theory (99). 
The robustness of the MI approach for dissimilar modalities can be enhanced via 
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the combined feature ensemble mutual information (COFEMI) technique which 
incorporates additional information for one of the modalities in the form of image 
features (91). The robustness and the results of this technique are highly 
dependent on the selection of the image features. The MI-based approach 
incorporated by the COFEMI technique has been used for registering WM to both 
exMR and inMR images (91) while the Spatial Weighting Mutual Information 
(SWMI) technique has been used for registering PWM to ERCinMR images (92), 
addressing the same problem focused on in the current study. While the SWMI 
work addressed the same challenging problem of registering in vivo MRI with 
PWM data presented in this work, only a limited number of cases were 
demonstrated.  While the SWMI method doesn’t require the identification of the 
capsule border it also demonstrated lower registration accuracy compared to 
LATIS with a DSC of 0.83 on average. 
Given the scope of registration problems best handled by the previously 
described methods, we desired a new approach which was more appropriate to 
register PWM and ERCinMR and required a minimum amount of a priori 
information. First of all, the existing methods available in the literature required 
an investigator, or sometimes feature recognition software, to identify sufficient 
numbers and distributions of control points to guide the registration between the 
histopathological and MRI images. Recognizing the fact that registration between 
two images requires some pre-defined controls, we observed that there were 
clearly some features that could be defined with reasonable precision. One 
feature was the prostate boundary and the others were larger internal structures 
like the central gland-peripheral zone boundary, transition zone, apex-
semicircular sphincter and bilateral nodules of benign prostatic hypertrophy. This 
addressed the challenge of identifying numerous control points with exact spatial 
correspondence between the source and target images as required by the BSp 
and TPS methods. Identification of landmarks was often difficult and the number 
of points would have been insufficient for guiding registration. The difficulty of 
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selecting spatially corresponding control points is evidenced by the large 
discrepancy between the number of points the two researchers selected for 
determination of registration accuracy. However, the identification of larger 
anatomic structures was always possible in our test cases. 
The second issue with the aforementioned methods was the underlying 
assumption of a continuous deformation field which is less appropriate when 
registration involves PWM data. Therefore, we developed a method based on the 
invariance of the image intensity function, which does not require the assumption 
of continuous deformation fields. This feature makes the resulting method 
suitable to handle the local distortions that lie within the PWM images such as 
the unfilled space or gaps between the QMHS. 
To address the discontinuous nature of the reassembled PWM images 
and to overcome the overall challenge of multi-modal registration, tri-intensity 
masks of both datasets taking into account the prostate border and large internal 
structures were used as the source and target images for registration.  While not 
the focus of this work, it could easily be envisioned that BSp and TPS could be 
used for registering the tri-intensity images in place of the local affine 
transformation chosen here however, the identification and selection of control 
points would still be necessary and a limiting factor to their successful 
implementation.  
3.5.2 Registration and Pathology Limitations 
Both LATIS, and the other referenced registration studies, have addressed a two-
dimensional registration problem. Therefore, an important requirement (i.e. the 
first assumption in LATIS) is that the source and target images originate from the 
same plane through the prostate. Even with careful attention to the sectioning 
protocol multiple factors can lead to axial planes which do not match between the 
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MRI and pathology, including non-linear shrinking of the tissue during fixation. 
This lack of correspondence would further complicate, if not eliminate, the 
possibility to find features for guiding registration.  The selection of control points 
used by TPS and BSp based on small structural features would arguably be the 
most affected. However, LATIS may be less sensitive to the same offsets due to 
the persistence of larger structural features through plane. The influence of both 
through-plane offsets and in-plane registration errors must be considered when 
evaluating the registration accuracy of annotated cancer regions from pathology 
to imaging.  The relative impact of any error would be greater for smaller areas of 
disease. 
 Additional limitations exist in the most apical and basal regions. As 
described in the sectioning protocol, the most apical section of the prostate is 
removed and cut in the sagittal orientation. Using LATIS in this orientation has 
not been explored to date. One obvious limitation is the absence of a complete 
capsule contour. In the base, several aspects of the sectioning protocol and the 
anatomy make identification of the prostatic capsule and assembly of the PWM 
difficult including, the ambiguous prostate-bladder border, amputation of the 
seminal vesicles and vasa deferentia at the base and shaving of the proximal 
urethral margin to a thickness prior to placement in the sectioning box. The end 
result is the absence of a well-defined capsule in the most basal slices which 
makes them difficult to handle with the proposed methods. 
Despite the previously described limitations, the sectioning protocol and 
registration methods have proven to be relatively robust in the cases studied to 
date.  In general, less than 15% of cases handled in our lab needed to be 
excluded from registration due to mismatches in slice orientation (i.e. an obvious 
violation of assumption No. 1) and  less than 3% of cases had to be excluded 
due to index lesions too for inferior or superior in the prostate. 
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3.5.3 Assessment of Registration Error 
The assessment of image registration accuracy in literature has been has been 
accomplished using a variety of error metrics. In the present study registration 
accuracy was calculated using 1) the dice similarity as a “global” metric for 
characterizing the registration of the tri-intensity images (i.e. capsule and large 
internal structures) and 2) corresponding landmarks identified manually in both 
source and target images to characterize registration accuracy of internal 
features of the prostate. Similar methods have been used in the literature to 
assess registration accuracy (101-109). 
The need to perform accurate registration between PWM and ERCinMR 
stems from the desire to use pathological results as the ground truth for 
interpreting the MRI results for determining the extent and aggressiveness of 
disease. A “perfect” registration would permit a reliable pixel–wise analysis of 
MRI with  respect to histopathology however, the ability to approach this ideal 
correspondence is difficult due to the complexity of the distortions and the limited 
information available to correct for them. To improve our registration method, 
future implementations could incorporate other MRI visible structures like the 
urethra.  The LATIS approach could also serve as a baseline method in a 
cascaded registration procedure, where additional registration steps 
incorporating other previously proposed strategies and information may be used 
to further improve the correspondence of salient features between the datasets. 
Using LATIS would be a valuable first step for the reasons stated above, 
including that 1) it relies on the selection of large structures rather than specific 
points which makes it more robust in cases where the prostate slicing and MRI 
imaging plane are not exactly the same, 2) it does not rely on image intensity 
from the multi-modal data and 3) it does not assume a smooth continuous 
deformation field, an assumption, which is violated in the case of the PWM data. 
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In the future improved error metrics for assessing registration accuracy 
would also be desired in order to compare LATIS with other registration methods 
and potentially cascaded approaches. Potentially this is possible by acquiring 
additional information in the process of generating the PWM and acquiring the 
ERCinMR data such as images of the gross pathology sections cut into quarters 
prior to paraffin embedding and imaging of the prostate after excision and before 
sectioning (exMR). The intermediate exMR acquisition step is useful because of 
similarity of MR signal intensities between exMR and ERCinMR images and 
superior axial resolution of the exMR scan excision of the tumor enabling 
accurate registration with PWM. This information may help elucidate the 
deformations present between the source PWM data and the target ERCinMR 
and provide a more complete characterization of the deformations to better 
evaluate other strategies which do not require the labor and time to acquire the 
additional data.  
In conclusion, the main geometric issues in histopathology-MR image 
registration are the distortions resulting from the use of an endorectal coil when 
acquiring the inMR data, the deformation due to removal, and fixation and 
distortion of individual QMHS which result in discontinuities in the final 
assembled PWM. In this work, this registration problem is addressed by using 
LATIS which involves identifying large internal structures along with the prostate 
boundary to guide registration. While the method to assess the registration 
accuracy was subjective, it is an important first step in the validation of the 
technique.   
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Chapter 4 Developing MP-MRI Cancer 
Predictive Models using Co-registered 
regions of Defined Disease  
This was a collaborative project primarily between Dr. Greg Metzger, Dr. Joseph 
Koopmeiners, Dr. Stephen Schmechel and me. My contribution consisted of 
assisting in scanning 70 clinical subjects and developing the analysis workflow 
which involves coordination, analysis and manipulation of: 
1. MRI DICOM images obtained on the scanner.
2. Anatomic and molecular digital pathology data stored on Aperio Servers at
the hospital.
3. Intermediate data generated within Matlab.
I incorporated a unified visualization environment based on OsiriX into the 
workflow as current analysis and visualization tools were found insufficient to 
handle the types of data required for MP-MRI model generation. This enabled 
simultaneous visualization of all derived MRI datasets, import and manipulation 
of registered areas of annotated cancer and generation of ROI location reports 
for subsequent analysis against co-registered pathologic markers. I generated all 
co-registered pathology cancer and non-cancer data used in the MP-MRI model 
and manipulated the statistical processing code in R statistical environment (110) 
to generate the different MP-MRI model results. 
4.1 Introduction 
In this chapter, the development of multiparametric models will be addressed for 
cancer detection from the quantitative data described in Chapter 2. Compared to 
the use of individual MRI datasets, multiparametric MRI (MP-MRI) models have 
also shown promise for improving PCa detection (41-47). The most relevant 
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previous studies are summarized in Table 4.1 and characterized by the following: 
the types of MRI datasets used, whether these were qualitatively or quantitatively 
evaluated, identifies which were region or voxel based, the type of pathologic 
“Gold Standard” used (i.e. biopsy or post-prostatectomy) and the target outcome 
(i.e. detection or grade). Langer et al. (41) constructed a 3 parameter logistic 
regression based model for mapping peripheral zone (PZ) tumors using ADC 
(Apparent Diffusion Coefficient), T2 and Ktrans at 1.5T. Matulewicz et al. (42) used 
an artificial neural network (ANN) model for automatic detection of cancerous 
voxels in the prostate from 1H-MRSI datasets at 1.5T. Poulakis et al. (46) 
developed an ANN model for predicting biochemical recurrence based on the 
pelvic coil MRI, PSA measurement, and biopsy Gleason score, after radical 
prostatectomy at 1T. Puech et al. (47) used generalized estimating equations 
(GEEs) to construct a computer assisted diagnosis (CAD) software capable of 
generating a standardized cancer suspicion score for suspicious foci detected in 
DCE-MRI T1-w images obtained at 1.5T. Anderson et al. (43) combined logistic 
regression and nearest neighbor classification to generate an  augmented model 
using DCE, DW (Diffusion Weighted) and MRSI (Magnetic Resonance 
Spectroscopy Imaging) datasets to predict PCa in the whole prostate. Litjens et 
al. (45) developed a Random Forest Classifier based CAD system to detect PCa 
in the whole prostate at 3T. Finally, Delongchamps et al. (44) used combinations 
of T2-weighted imaging, DCE and DWI for the detection of PCa in the whole 
prostate at 1.5T.  
The process of assessing -MP-MRI’s ability to predict disease is 
determined through correlation with a pathologic Gold Standard. This correlation 
involves mapping the information from pathology (i.e. grade and location of 
identified disease) onto the MRI data and has been accomplished through a 
variety of methods in the literature:  manual mapping of regions of interest (ROIs) 
(41); visual mapping of sextants (42) or octants (43,44); mapping locations of 
graded MR guided biopsy specimens (45) or calculated Gleason scores 
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(43,46,47). The process of correlating manually drawn regions of interest (ROIs) 
(41) on the MRI corresponding to identified areas of disease on pathology 
introduces potential biases of both ROI drawing and placement.  Studies that use 
pathology mapped regions  in the form of sextants(42) or octants (43,44) are 
limited due to the loss of underlying voxel heterogeneity. The limitations of these 
methods are addressed in the current methods where a direct mapping of 
digitally annotated regions of graded disease are mapped to the MRI image 
using LATIS, detailed in Chapter 3 (48).  
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In comparison to the studies mentioned in Table 4.1, this chapter presents a 
predictive model building approach that offers the following distinct advantages 
that stem from the use of co-registered pathology data. 
1. Reduce pathology correlation bias: The use of directly mapped co-registered
regions of Post PPP onto in-vivo MP-MRI images is free from biases outlined
above.
2. A pixel-wise analysis approach that allows investigation of apparent non-
coincidence of quantitative MR (qMR) parameters.
3.  All data use in the modeling is quantitative with the potential to apply
prospectively to MP-MRI data acquired without any quantitative assessment 
or interaction. 
4. All lesions with volumes greater than 0.19 cc (maximum volume 17cc) were
included in the modeling thus not limiting the results to the detection of large
volumes of disease.
5. A separate model is presented for discriminating cancer from non-cancerous
central gland tissue.
6. Inclusion of all pixels from the prostate – both from cancer and non-cancer
allows this model to approach an ideal situation where all available input data
is used for model generation. This also allows the full heterogeneity of both
cancerous and non-cancerous regions to be accommodated in the model and
more closely represent the type of data a model would have to handle when
applied in a clinical setting.
In this chapter we develop and validate several models for MP-MRI PCa 
detection in the whole prostate, central gland (CG) and peripheral zone (PZ) 
using voxel-wise post prostatectomy pathology (PPP) registered cancer and non-
cancer data obtained zonally or from the whole prostate. 
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4.2 Methods 
Figure 4.1 Process of acquiring data for predictive model generation. 
From the patient studies defined in Chapter 3 Section 3.1, input data (i.e. 
MP-MRI data) and output data (i.e. pathology data) were defined for 
development of predictive models. This process is outlined in Figure 4.1 and 
provided below: 
1. Assemble the annotated PWM pathology data into volumes and combined
capsule annotations and cancer annotations into lesions.
2. Identify coincident slices between anatomic T2w MRI and pathology for
registration.
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3. Define the pseudo-capsule border and division between the PZ and CG on
the anatomic T2w Images.
4. For a given slice pair (i.e. MRI and pathology), perform LATIS deformable
registration using the capsules and large internal structures defined on both
pathology and T2w images.
5. Map areas of cancer from pathology onto anatomic MRI.
6. Using the mapped areas of disease classify all voxels in the anatomic T2w
MRI slice as non-cancer PZ, non-cancer CG or PCa.
7. Map this voxel classification from the T2w anatomic MRI to the interpolated
quantitative MRI (qMR) datasets accounting for any motion either through-
plane or in-plane using a manual rigid body approximation within OsiriX.
8. Extract all qMR from non-cancer and cancer regions for use in developing the
predictive models.
9. Perform LASSO regression on subsets of the data to develop regions specific
or whole organ predictors for prostate cancer detection.
4.2.1 Data for Model Development 
Annotations of cancer were defined by a study pathologist on the digitized 
pathology as detailed in Chapter 2 Section 2.3.3.  The annotated slides were 
assembled into pseudo-whole mounts and then into complete prostates.  This 
volumetric reassembly allowed continuous volumes of cancer to be linked 
together and defined as lesions. A given lesion can be characterized by its size 
given in units of cm3 by standard methods knowing the resolution of the digitized 
pathology, knowledge of the pathologic block thickness and accounting for a 
shrinkage factor of 25% (111). For a given prostate, the lesion with the highest 
grade or largest volume was identified as an index lesion (IL). Any other 
significant volume of disease identified in the prostate were also identified as 
secondary (SL) or tertiary (TL) lesions based on decreasing grade/volume. 
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The MRI slice location corresponding to the center of the cancer lesion 
defined on pathology was determined by verifying the approximate distance from 
the apex and existence of similar anatomic features. Annotated regions of cancer 
from pathology were then registered to the corresponding anatomic T2w image 
using LATIS (Chapter 4(48)) which has been demonstrated to have a registration 
accuracy of 1.54±0.64mm and a Dice Similarity Coefficient of 0.991±0.004.  
The goal at this point is to define the following regions: non-cancer PZ 
(NCPZ), non-cancer CG (NCCG), cancer PZ (PCPZ) and cancer CG (PCCG). This 
process requires several steps.  First, the anatomic T2w images were further 
segmented into two regions (i.e. CG and PZ) using a semi-automated 
segmentation program (Segasist, Ontario, Canada). To generate the non-cancer 
regions, all registered cancer masks were first subtracted from the prostate’s 
pseudo-capsule mask determined from the anatomic T2w data.  The cancer 
masks were first dilated by 3 pixels (~1.5 mm) before subtraction to 
accommodate for mis-registration. The NCCG was then given as the intersection 
of the prostates pseudo-capsule (eroded by 1 pixel) minus the regions of cancer 
and the segmented CG region.  The NCPZ region was the remainder of the voxels 
from the eroded and cancer subtracted pseudo-capsule. Figure 4.2 (a, b, c) 
shows three examples of how these regions are defined in the prostate for 
various cases.  
Next, these regions, and the voxels within them, need to be identified on 
all the qMR datasets.  As there is a possibility of motion between scans during an 
MP-MRI study, accommodations had to be made to shift the regions detailed 
above. As methods to register between the MP-MRI datasets are not yet 
developed, a rigid body deformation was assumed to map the regions from the 
T2w anatomic series to the qMR data.  The through-plane (12/124) shifting and 
in-plane (35/124) translation  for qMR data sets was manually determined to 
correct for changes due to patient motion and EPI distortion. This was done 
using OsiriX (Pixmeo, Geneva, Switzerland) software, where all qMR data sets 
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along with the anatomic T2w data with registered cancer regions could be 
displayed simultaneously. Internal features and the borders of the prostate were 
used to determine proper adjustment on each qMR dataset. 
Figure 4.2 Visualization of cancer and non-cancer regions used in model generation 
from four patients on the un-interpolated T2w anatomic images. PCa is confined to (a) 
CG only (b) PZ only (c) both CG and PZ. (d) shows an example of a non-cancer user 
defined ROI in the CG (NCCG-ROI). PC stands for Pseudo Capsule. The CG (green) and 
PZ (yellow) annotations provided the original segmentation of the two prostatic regions. 
These annotations are mostly overlapped by the other annotation therefore they only 
appear as broken curves in this figure. 
4.2.2 Non-cancer from user defined ROIs 
Non-cancer regions determined from the process above included all non-
cancer pixels from the transverse slice of the prostate which intersected the 
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center of the lesion of interest.  Especially for CG, this presents a real challenge 
both because of the abundance of benign disease but also due to the inclusion of 
the urethra and the fibromuscular cap which have qMR characteristics similar to 
cancer even when healthy.  To explore the impact of non-cancer voxel selection 
on the predictive models, a separate set of non-cancer CG data was identified 
from user defined ROIs. These regions, referred to as NCCG-ROI, were at least 9 
mm away from cancer and avoided the urethra and fibromuscular cap.   
4.2.3 Predictive Modeling 
Table 4.2 Characteristics of data pool (number, name, origin and type of cancer and 
non-cancer data) used in model generation. 
Based on the different combinations of cancer and non-cancer ROIs 
available, four pools of data were generated as shown in Table 4.2. Pool I and II 
enabled detection of cancer from non-cancer in the PZ and CG, respectively. 
Pool III was created to predict cancer from non-cancer across the whole prostate 
irrespective of zone. Because the CG data in pools I through III were derived 
from all pixels outside the PZ but in the prostate, it included structures such as 
the urethra and anterior fibromuscular cap.  To investigate how the CG voxel 
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selection impacted the model development, another data pool (IV) was 
constructed using NCCG-ROI data.  
Data pools (I-IV) were filtered to exclude zero voxels from failed 
parametric mapping, primarily from the DCE-MRI and T2 mapping datasets. The 
remaining voxels were used to generate cancer and non-cancer median values 
for each qMR parameter, the correlation between qMR parameters, ROC 
analysis results for each parameter and ROC analysis results for models based 
on combinations of the parameters. A p-value comparing the composite marker 
to the single best marker was also calculated. One-sided p-values were reported 
instead of two-sided p-values to show the performance of multiple markers 
compared to a single marker. 
All predictive models were run on only those subjects with complete 
records for all the qMR parameters. The classification accuracy of various 
approaches (Logistic regression, Generalized Estimating Equations, Naive Bayes 
Classifier, Support Vector Machines and Least Absolute Shrinkage and Selection 
Operator (LASSO) (112) in PCa prediction was tested on Data Pool I and was 
compared with that obtained from an individual qMR parameter (ADC). This 
comparison was done for each approach using all 9 parameters (ADC, T2-TSE, 
T2-SEMC, T1-DESPOT1, T1-TSE, Ktrans, Kep and AUGC) and a 5 parameter 
subset comprised of (ADC, T2-TSE, Ktrans, Kep and AUGC). Receiver Operator 
Characteristic (ROC) based Area Under ROC curve (AUC) and ROC (0.1) 
(Sensitivity corresponding to 90% Specificity) statistics were calculated for each 
approach. Based on the results of this comparison we chose a LASSO method 
based modelling approach (112).  
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Table 4.3 Classification accuracy summaries for various modeling approaches used to 
develop a MP-MRI model for predicting PCa using cancer and non-cancer data in the 
peripheral zone only (Data Pool I). The LASSO 5 parameter approach was chosen 
based on these results. 
Feature selection and modeling was performed by logistic regression with 
the LASSO method run in RStudio (113) utilizing the R statistical environment 
(110) . All statistical analysis was done using standard R packages such MASS 
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(114), geepack (9,14,115), e1071 (22), kernlab (116), rje (117), pROC (13) and 
ROCR (10). After the initial training and validation sets were established forward 
stepwise selection was performed using leave one out cross validation to select 
the optimum subset of the 8 qMR parameters. The optimum subset LASSO 
model was applied to all the data pools (I-IV). For each pool, the corresponding 
best LASSO model was called L#P_PZ, L#P_ALL, L#P_CG, L#P_CGROI 
respectively where # is the optimum number of qMR parameters. Bootstrap 
methods were used in R for computing standard errors and confidence intervals.    
For each data pool, ROC curve plot showing the best LASSO model along 
with best performing single predictor was generated. The ROC0.1 (sensitivity 
corresponding to 90% specificity) cutoff value was also shown on the plot. Using 
the ROC0.1 cutoff, plots of sensitivity of each model for each cancer region versus 
the number of voxels in the cancer region were generated. A composite 
biomarker score (CBS) for each pixel in the cancer region was generated based 
on the linear regression coefficient output from the model, such that,  
 ??? = ?? ????????? ? ?????? ? ??????? ? ?????? ??? ? ??????? ? ??????? (4.1) 
Where ß0 and ßqMR are the LASSO model output linear regression coefficients for 
respective qMR parameters and n is the optimum number of qMR parameters 
needed to create the best performing model. The sensitivity of the model per 
cancer region was calculated by dividing the number of voxels whose CBS was 
greater than the ROC0.1 cutoff (model predicted cancer) by the total number of 
voxels (true positives) in the cancer region. The specificity of the model per non 
cancer region was calculated by dividing the number of voxels whose CBS was 
less than the ROC0.1 cutoff value (model predicted non-cancer) by the total 
number of voxels (true negatives) in the non-cancer region. This method of 
visualizing region-wise sensitivity and specificity was useful in assessing the 
performance of the model based on the size of the cancer/non-cancer region. 
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Image registration and qMR parameter dataset generation was done using 
the Matlab (MathWorks, Natick, MA). ROC Curves were plotted in Origin 
(OriginLab, Northampton, MA). Sensitivity per cancer region and specificity per 
non cancer region plots were generated in Microsoft Excel 2010. 
4.3 Results 
The total number of cancer and non-cancer voxels per data pool are tabulated in 
table 4.4. Median, maximum and minimum values of qMR data from the four data 
pools used for model generation are summarized in Table 4.5. Correlation 
between qMR parameters was, in general, weak, with the highest correlation 
seen between DCE-MRI parameters. Correlation coefficients among the DCE-
MRI ranged from r = 0.92 between Ktrans and AUGC, r = 0.68 between Kep and 
Ktrans (r = 0.68) and r = 0.52 between Kep and AUGC where r is the correlation 
coefficient. 
Table 4.4  Total number of cancer and non-cancer voxels from each data pool used for 
Single Predictor (SP) and Multi Predictor (MP) model generation. The difference in the 
number of initial and final cancer and non-cancer MP voxels in CG, ALL and CGROI pools 
is due to a sampling cutoff of 200 voxels from each region used in the R code for faster 
processing. A comparison of the results obtained using all voxels with those obtained 
using a 200 voxels cutoff showed no difference.  
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Table 4.5 Median, 95% confidence intervals for qMR cancer and non-cancer values 
from data pools used in 5 parameter model generation. Also shown are the p values 
showing whether cancer qMR values are statistically significant from non-cancer values.  
Figures 4.3,4.4,4.5 and 4.6 show the results for LASSO models applied to data 
pools I to IV respectively. Each figure includes:  
a) A Receiver Operator Characteristic (ROC) curve for the best performing
LASSO model and single predictor.
b) Table showing AUC and ROC0.1 values for each individual predictor and
optimum parameter subset based on stepwise addition of significant qMR
parameters for each LASSO model.
c) Sensitivity per cancer region plotted vs. number of pixels in each cancer
region.
d) Specificity per non-cancer region vs. number of pixels in each non-cancer
region.
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Figure 4.3 L5P_PZ model results. (a) ROC curve for L5P model and ADC showing the 
ROC0.1 cutoff (b) Table showing AUC and ROC0.1 values for each single predictor and 
L5P_PZ model. L5P_PZ results are shown in order of incremental addition of significant 
predictor to the model. Plots (c) and (d) show the L5P_PZ model’s performance for 
cancer and non-cancer regions of different size by the calculation of sensitivity per 
cancer region and specificity per non cancer region. 
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Figure 4.4 L4P_CG model results. (a) ROC curve for L4P_CG model and ADC showing 
the ROC0.1 cutoff (b) Table showing AUC and ROC0.1 values for each single predictor 
and L4P_CG model. L4P_CG results are shown in order of incremental addition of 
significant predictor to the model. Plots (c) and (d) show the L4P_CG model’s 
performance for cancer and non-cancer regions of different size by the calculation of 
sensitivity per cancer region and specificity per non cancer region. 
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Figure 4.5 L4P_ALL model results. (a) ROC curve for L4P_ALL model and ADC 
showing the ROC0.1 cutoff (b) Table showing AUC and ROC0.1 values for each single 
predictor and L4P_ALL model. L4P_ALL results are shown in order of incremental 
addition of significant predictor to the model. Plots (c) and (d) show the L4P_ALL 
model’s performance for cancer and non-cancer regions of different size by the 
calculation of sensitivity per cancer region and specificity per non cancer region. 
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Figure 4.6 L5P_CGROI model results. (a) ROC curve for L5P_CGROI model and ADC 
showing the ROC0.1 cutoff (b) Table showing AUC and ROC0.1 values for each single 
predictor and L5P_CGROI model. L5P_CGROI results are shown in order of incremental 
addition of significant predictor to the model. Plots (c) and (d) show the L5P_CGROI
model’s performance for cancer and non-cancer regions of different size by the 
calculation of sensitivity per cancer region and specificity per non cancer region. 
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Figure 4.7 72 year old man with biopsy-confirmed PCa with Gleason score, 6 on the 
right side PZ of the prostate. (a): PWM with tumor outlined in blue. (b)Corresponding T2-
weighted MRI with registered tumor region overlay, and (c) composite biomarker score 
(CBS) map acquired using a L5P_PZ model with registered tumor region outline in 
black. Associated CBS colorbar shows ROC0.1 cutoff. The PZ tumor region can be seen 
appreciated in against the background in the CBS map and is composed of pixels with 
CBS > cutoff. 
Generation of a CBS map using the L5P_PZ model for a representative case 
where the tumor is present in the right PZ is shown in Figure 4.7  
Based on AUC calculations, ADC was the best performing single 
parameter for detection of PCa in data pools PZ, CG and ALL.  T2-TSE was the 
best single predictor for CGROI. The best performing LASSO models for data 
pools I-IV based on AUC values in incremental order of significant qMR 
parameters were L5P_PZ (ADC, AUGC, Kep, T2-TSE and Ktrans), L4P_CG (Kep, 
ADC, T2-TSE, ,AUGC and Ktrans), L4P_ALL (ADC, Kep, T2-TSE and AUGC), 
L5P_CGROI (Kep, ,ADC, T2-TSE, AUGC and Ktrans).  
L5P_PZ was the best performing model among all the other LASSO 
models with the highest AUC (0.84(0.81, 0.90)) and ROC0.1 value (0.63(0.54, 
0.78)). Among individual predictors, ADC had the highest AUC (0.82(0.77, 0.87)) 
and ROC0.1 value (0.60 (0.47, 0.71)) for data pool I. Among all the models 
L5P_PZ shows the least variation in sensitivity per cancer region w.r.t. cancer 
region size whereas L4P_CG shows the least variation of specificity per non 
cancer region w.r.t non cancer region size. L4P_CGROI was not considered in the 
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specificity comparison as data pool IV includes annotated non-cancer regions 
that lack the heterogeneous makeup of non-cancer regions from data pools I-III. 
4.4 Discussion 
This chapter demonstrates the results of predictive MP-MRI models for PCa 
detection based on co-registered pathology as the gold standard for defining both 
regions of cancer and non-cancer. Manually transferring regions of cancer from 
pathology to imaging can bias the input data used to generate the predictive 
models. In this manual process, the features of the target image can’t help but 
greatly influence the manual interpretation of the pathologic ROI on the MRI. The 
first issue is, which MRI dataset should be used.  As the features of cancer on T2, 
ADC and DCE-MRI are not always co-incident or even present, the transferred 
pathologic ROI would necessarily be different dependent on the MRI dataset 
chosen as the basis for transference.  Second, it is not always clear where the 
cancer region is on the MRI especially in smaller volumes of disease or around 
the borders of disease where less distinct features are available due to partial 
voluming or lower grade disease.  In this case, how is the region of cancer 
transferred?  Most likely the process is different in this case where there are 
more distinct features of disease to assist in the region drawing on MRI.  Finally, 
in cases of distortion between MRI and pathology, the region drawing becomes 
even more user dependent as local landmarks, which are sometimes hard to 
find, are not clearly identifiable close to the region where the ROI is needed. The 
use of pathology co-registered regions used for model development as shown in 
this work reduces potential bias in the determination of the training data regions 
and more accurately represents the wide range of values and spatial 
correspondence encountered in a multi parametric image set, compared with the 
use of summary values. This non-biased selection of cancer and inclusion of all 
non-cancer pixels is unique in this work. 
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The developed LASSO models combine information from multiple qMR 
datasets to generate a composite predictor score (CBS) to assess the risk of 
malignancy, precluding review of each MRI scan separately. While Figure 4.7 
shows an example of a CBS map where a cutoff corresponding to the ROC0.1
was used, the determination of an appropriate cutoff is still required for the 
application of each model prospectively and most likely will depend on the clinical 
application.  
All the four multi-parametric LASSO models were able to better distinguish 
between voxels in normal and malignant prostate tissue, as determined 
quantitatively through the calculation of the mean area under the ROC curve, 
AUC compared to individual qMR parameters as shown in figures 4.3, 4.4, 4.5 
and 4.6. The AUC values of the single and MP-MRI models lies within the range 
of studies shown in Table 4.1 (AUC range: [0.692, 0.999]); however, is important 
to note that since these models predict cancerous voxels in the prostate the ROC 
statistics are calculated voxel-wise and not region-wise.  
The L4P_ALL and L4P_CG models show that four qMR parameters are 
most effective at detecting PCa in the whole prostate or CG alone however the 
best qMR parameters to use depends on the data pool. The plotted sensitivity 
per cancer region and specificity per non cancer region versus region size shows 
the performance of each model across regions of different sizes. It is important to 
note that these plots are based on ROC0.1 cutoff and therefore give an expected 
high specificity. It would be desirable to have a cancer detection model with 
consistent sensitivity irrespective of lesion size. Among the four models L5P_PZ 
shows the least sensitivity to lesion size. The most likely reason for this is the 
absence of CG data from the non-cancer pool greatly reducing variability of the 
non-cancer data used for model development. 
Training and test data for LASSO model generation used cancer data in 
combination with different pools of non-cancer voxels from CG and PZ tissue in 
the prostate. The different combinations were investigated because the 
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parameter values measured in the central gland differ from those measured in 
the peripheral zone and therefore, potentially, each zone may benefit from a 
different model. The limited number of CG lesions in the entire patient cohort (9 
in 46 patients) lead to development of models L4P_CG and L5P_CGROI based on 
all cancer data (i.e. both GZ and PZ cancers) but different types of non-cancer 
data obtained from the CG. In L4P_CG, non-cancer data was obtained from 
NCCG whereas L5P_CGROI had non-cancer data obtained from NCROI. In 
L4P_CG, the use of NCCG obtained from prostates with CG cancer annotations 
along with those from prostates with PZ cancers allowed the assessment of 
model performance in detecting PCa in CG using a larger non-cancer CG data 
pool. In L5P_CGROI, ROIs for ‘normal’ data were restricted to exclude periurethral 
and fibromuscular cap regions that exhibit cancer-like characteristics as seen on 
MRI. It is possible that these ROIs may also contain regions of benign disease 
(e.g. Benign Prostate Hyperplasia)..  
As seen from the difference between the initial and final number of cancer 
voxels in Table 4.4 in data pools II-IV 200 voxels were sampled from each cancer 
and non-cancer region. A comparison of all four model results obtained using all 
cancer & non cancer voxels versus a subset of 200 voxels showed no significant 
difference. This showed that after a certain point adding additional observations 
(voxels) from a single cluster (slice) provided essentially no information for 
estimating the predictive model other than slowing down the computer code used 
for fitting the model.   
4.5 Conclusion 
In this chapter the development of a multi-parametric MRI model to 
identify cancerous voxels in prostate tissue generated using pathology–MR 
coregistered datasets has been presented. Single and MP-MRI models for PCa 
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detection were obtained from pathology co-registered T2, ADC, and DCE-MRI 
datasets with the final MP-MRI model including ADC, T2-TSE, Ktrans, Kep and 
AUGC. These MP-MRI models can be used for the prediction of cancerous 
voxels in the peripheral zone, central gland or the whole prostate. 
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Chapter 5 Application of Methods to High 
and Ultra High-Field MP-MRI 
5.1 Context 
Multiparametric MRI studies of the prostate at ultra-high magnetic field(UHF) (i.e. 
7T)  carry with them the promise of improved disease characterization resulting 
from improvements in SNR, better parallel imaging performance and increased 
spectral resolution. This advancement to higher fields comes with its own 
disadvantages including higher motion sensitivity, increase in local specific 
absorption rates (SAR), B1 field inhomogeneities and susceptibility artifacts. 
While initial MRI studies at 7T have been performed to explore the potential for 
improved PCa detection using anatomical imaging (118) and functional imaging 
studies (4,119), much work is still needed. One of the challenges in conducting 
DCE-MRI studies on the prostate at 7T is a limited understanding of the 
increasing influence of T2* on T1w acquisitions. While r1 relaxivity has been 
shown to slightly decrease with increasing field strength, r2* relaxivity increases 
dramatically and can dominate signal changes especially at higher CA 
concentrations. The standard conversion of change in signal intensity to change 
in concentration is affected by R2* which is typically ignored as it is assumed that 
TE << T2*, however this is no longer the case at 7T. The increasing R2* with field 
strength has a significant effect on the enhancement curves in tissue and 
catastrophic effects on the signal in the vasculature (4). To understand both R1 
and R2* relaxivity, the following study was performed looking at both blood and 
saline at both 3T and 7T. The findings are relevant to paramagnetic contrast 
agent studies performed at UHF including DCE-MRI performed outside the 
prostate and vascular studies performed with contrast at throughout the body. 
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The rest of this chapter is adapted with permission from the following publication: 
Kalavagunta, C., Michaeli, S. and Metzger, G. J. (2014), In vitro Gd-DTPA 
relaxometry studies in oxygenated venous human blood and aqueous solution at 
3 and 7 T. Contrast Media Mol Imaging, 9: 169–176. doi: 10.1002/cmmi.1568   
This was a collaborative project between Dr Greg Metzger, Dr Shalom Michaeli 
and me. I devised a ways to obtain venous blood, oxygenate it, generate highly 
calibrated serial concentrations of Gd-DTPA and present the samples for 
experimentation in the MRI scanner while keeping everything at 37±2 °C. For 
post processing I performed relaxometry measurements calculations and fitted 
parameters accounting for propagated errors which greatly increased confidence 
in the final results. 
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5.2 Synopsis 
In-vitro T1 and T2* relaxivities (r1 and r2*) of Gd-DTPA (GaD) in oxygenated 
human venous blood (OVB) and aqueous solution (AS) at 3T and 7T were 
calculated. GaD concentrations ([GaD]) in OVB and AS were prepared in the 
range 0-5 mM. All measurements were acquired at 37±2 ºC. At both 3T and 7T, a 
linear relationship was observed between [GaD] and R1 in both AS and OVB. At 
7T, r1 in AS decreased by 7.5% (p = 0.045) while there was a negligible change 
in OVB. With respect to R2*, a linear relationship with [GaD] was only observed in 
AS, while a more complex relationship was observed in OVB; quadratic below 
and linear above 2 mM at both field strengths. There was a significant increase of 
over four-fold in r2* with GaD in OVB at 7T (for [GaD] above 2mM, p <<0.01) as 
compared to 3T. Furthermore, in comparison to r1, r2* in AS was less than two-
fold higher at both field strengths while in OVB it was ~twenty-fold and ~ninety-
fold higher at 3T and 7T, respectively. This observation emphasizes the 
importance of r2* knowledge at high magnetic fields, ≥3T.  The comparison 
between r1 and r2* presented in this work is crucial in the design and optimization 
of high field MRI studies making use of paramagnetic contrast agents. This is 
especially true in multiple compartment systems such as blood where r2* 
dramatically increases while r1 remains relatively constant with increasing 
magnetic field strength. 
5.3 Introduction 
The paramagnetic effectiveness of a contrast agent (CA) is measured by its 
relaxivity which is defined as the rate by which the relaxation rate changes per 
unit molar CA concentration. Typically the effect of clinically used paramagnetic 
gadolinium based contrast agents on the longitudinal relaxation rate constant 
R1≡1/T1 is of most interest. However, understanding CA based changes in 
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R2*≡1/T2*, a function of both spin-spin interactions and local magnetic field 
inhomogeneities, is becoming more important as clinical and research endeavors 
expand into ever increasing magnetic fields. The increasing R2* effect with 
gadolinium based CAs at higher fields compete with the T1-weighted signal 
increase relied upon in post-contrast anatomic imaging, contrast enhanced 
angiography studies and dynamic contrast enhanced MRI (DCE-MRI). Increasing 
concentrations of CA result in higher R1 values and increased signal on T1-
weighted acquisitions while also producing higher R2* which disproportionately 
decreases signal at higher concentrations. Based on the results determined in 
this study, sub-millisecond T2* relaxation times at 7T are possible with Gd-DTPA 
concentrations ([GaD]) of 5 mM in the blood.  Such concentrations can easily be 
reached in-vivo when high injection rates of 3 ml/s are used (120) such as in 
DCE-MRI studies of the prostate.  
Previous studies have shown that, without correcting for T2* signal 
attenuation, subject dependent determination of the arterial input function was 
impossible for such studies (4). Similar effects are expected to negatively impact 
other contrast enhanced studies when performed at 7T such as first pass 
perfusion and angiography exams relying on T1-weighted enhancement 
(5).Understanding the field dependent relationship between the two relaxation 
rate constants with respect to CA concentration in blood can be undertaken by 
defining both R1 and R2* relaxivities, r1 and r2* respectively, and will be necessary 
for understanding the tradeoffs of using gadolinium based CAs at high fields and 
in the optimization of both acquisition parameters and injection paradigms. While 
there is a wealth of information investigating the relaxivity of gadolinium based 
CA in the literature, there are also an equal number of varying acquisition 
methods and experimental conditions which can greatly vary the results. 
Therefore, the goal of this work was to use consistent experimental methods at 
both 3T and 7T to determine r1 and r2*. For the paramagnetic CA, the relaxivity is 
a function of the motional correlation times, which includes several dynamic 
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components characterizing electron–proton dipolar coupling (121) and involving 
the magnetic moment of the metal ion. As the solvent of the CA has a 
tremendous effect on the relaxation properties, we investigated the relaxivity in 
both an aqueous solution (AS) and in fully oxygenated venous blood (OVB), both 
at physiological temperatures of 37±2°C. Because of its prominence in the 
literature and clinically use in our institution and elsewhere, Gadolinium-DTPA 
(MagnevistTM, Bayer, Germany) (GaD) was the CA used in this study.  
5.3.1 Theory 
The addition of a paramagnetic CA like GaD to a solution increases both 
relaxation rate constants R1 and R2. The observed R1,2(obs) after addition of GaD 
is the sum of the native relaxation rate of the solution R1,2(N) plus any contribution 
from GaD defined as R1,2(GaD). Thus R1,2(obs) = R1,2(N) + R1,2(GaD) (assuming 
independence of the relaxation pathways). In dilute solutions of GaD the 
observed relaxation rate constant R1 is assumed to be linearly dependent on 
[GaD]. The slope of the dependence is the relaxivity and the y-intercept is the 
native relaxation rate of the sample prior to the addition of GaD i.e. R1,2(obs) = 
r1,2(N)×[GaD] + R1,2(N), where r1,2(N) is the relaxivity defined as the incremental 
increase in the relaxation rate per unit concentration of GaD. The apparent 
transverse relaxation rate constant R2* is defined as R2* = R2 + R2’, where R2* is 
the observed transverse relaxation rate. R2 is the spin–spin relaxation rate 
constant and characterizes fluctuating magnetic field inhomogeneity effects, and 
R2’ (R2’≡1/T2’) is that induced by the local magnetic field inhomogeneities within 
the voxel (122).   
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5.4 Methods 
Commercially available formulation of GaD, having a concentration of 0.5 M, was 
mixed with OVB and AS to obtain final concentrations in the range 0-5.18 
mM(OVB) and 0-4.83 mM(AS), respectively.  
5.4.1 OVB Sample Preparation 
Venous human blood for this study was collected in a Vacuette heparin 
vacutainer (Greiner, Monroe, NC) through venipuncture using a standard 23-
gauge butterfly needle from a healthy donor. A high gauge needle was used to 
minimize hemolysis during blood collection. The tube was then gently inverted six 
times to thoroughly mix the blood in the vacutainer with heparin. This was done 
to avoid blood clot formation which would have rendered the specimen 
unacceptable for use. The blood in each vacutainer was then collected in a 1L 
side arm conical flask by pouring it slowly along the wall. The blood was then 
exposed to moist O2 and air using an in-house oxygenation apparatus. In this 
setup, dry O2 from the cylinder was passed through a conical flask containing 
distilled water (Kandiyohi Bottled Water Co., Willmar, MN). The resulting moist O2 
was then passed through a pressure gauge before interacting with the venous 
blood in the conical flask. The moist O2 pressure was maintained at 5-10 SLPM 
(standard liters per minute) during oxygenation. The conical flask was stirred 
gently for 1.5 hours until the sO2 reached 100%. An iStat (Abbott Point of Care 
Inc., Princeton, NJ) portable clinical analyzer was used to measure hematocrit 
(Hct), sO2 and pO2. A blood gas analyzer (Rapidlab-248, Siemens, Deerfield, IL) 
was used to measure pO2. The final pO2 (293.8 mmHg) was much higher than 
that of arterial blood (95 mmHg)(123).  
A pO2 decrease in plastic tube stored blood samples due to metabolism 
has been reported (124). This drop in pO2 can be attributed to oxygen 
consumption by leucocytes in blood and diffusion of oxygen through the walls of 
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the plastic tube. While T1 is known to have a slight linear dependency on pO2 (6), 
a high pO2 (hyperbaric O2) was chosen to ensure that the blood sO2 stayed 
above arterial blood sO2 levels (>94%) through the duration of the MRI 
measurements.  
5.4.2 GaD Solution in AS and OVB Preparation 
A 0.1 M HEPES buffer solution was used to maintain the pH of distilled water at 
7. GaD samples in AS were made by adding [GaD] to this buffer solution. OVB
obtained earlier was used as the solvent for making the GaD arterial blood 
solutions. A Corning (Corning Inc., Corning, NY) 15mL clear polypropylene 
centrifuge tube was placed on a Mettler AM100 electronic balance (Mettler-
Toledo, Inc., Columbus, OH). Microscopic volumes of GaD were added to the 
tube using a micropipette and the weight was recorded. This was followed by 
adding OVB or 0.1M (pH-7) HEPES solution to the tube and the final weight of 
the solution was recorded. The concentration accuracy of the GaD samples was 
calculated based on the weight measurements. Using the recorded weights and 
densities of GaD, human blood and distilled water at 22°C the final [GaD] 
obtained were, GaD in OVB: 0.00, 0.58, 1.12, 1.79, 1.98, 2.36, 2.88, 3.70, 3.90, 
4.38, 5.18 mM. GaD in AS:  0.0, 0.43, 1.00, 1.48, 1.93, 2.42, 3.05, 3.42, 3.90, 
4.42, 4.83 mM. 
5.4.3 Phantom Setup 
For both OVB and AS studies a plastic holder was used to house the 5 ml 
polystyrene round bottom test tubes containing the various [GaD] solutions. The 
holder was placed in a perforated container and surrounded by water bath 
tubing. A larger container then housed the whole setup and was filled with 0.45% 
saline solution to facilitate B0 shimming over the phantom, to load the transmit 
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coil and provide efficient heat transfer from the water bath hose. All studies were 
performed at a temperature of 37±2 °C. This temperature was maintained by 
pumping heated water through the water bath tubing (Thermo Scientific Neslab 
RTE- 7 Digital One). MR images of the phantom setup are shown in Figure 5.1. 
The temperature was monitored using a thermistor (YSI 400 series) positioned in 
the water bath but away from the sample tubes and a DigiSense (Cole-Parmer, 
Chicago, IL) Temperature Controller. Blood oxygenation (sO2, pO2) and Hct were 
measured before and after each set of T1, T2* experiments. Each blood phantom 
sample was gently turned upside down three times to ensure mixing before 
placement inside the scanner.  
5.4.4 MR Instrumentation 
All 3T measurements were performed on a Siemens Magnetom Trio scanner. 
Signal reception was achieved using a 12 channel head coil. RF transmission 
was performed using the scanner body coil. All 7T measurements were done on 
a Magnex 7T, 90 cm bore magnet with Siemens console and head gradients 
using a 16 channel transceive head coil.  
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Figure 5.1 (a) Axial and (b) sagittal scout images of the phantom setup. Legend: 1, 
water bath tubing; 2, outer plastic container; 3, 0.45% saline water; 4, vial; 5, vial holder; 
6, inner plastic container. Coronal view of the oxygenated venous blood (OVB) phantom 
from the first echo of the multi-echo acquisition used for calculating R2* for (c) 3 T and 
(d) 7 T. Coronal view of the OVB phantom from the TI = 20 ms, inversion recovery- turbo 
flash (IR-TFL) acquisition for (e) 3 T and (f) 7 T. The location of circular regions of 
interest used for data analysis within each acquisition for the zero GaD vial are shown in 
(c)–(f). 
5.4.5 T1 Measurement 
Multiple inversion recovery turbo flash (125) (IR-TFL) acquisitions were used to 
measure T1 by varying the inversion delay. The inversion pre-pulse was 
accomplished with a non-selective adiabatic inversion pulse.  Imaging 
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parameters for the IR-TFL sequence include: TR, 10 s; TE, 1.33 ms (3T), 1.05 
ms (7T); nominal flip angle, 6°; acquisition matrix, 128²; field of view, 190 mm; 
slice thickness, 3.5-5.0 mm; number of excitations NEX= 2; bandwidth per pixel, 
1000 Hz (3T), 1395 Hz (7T).  The inversion time (TI) was varied from 20 to 9000 
ms (20-30 TIs). A centrically ordered phase encode ordering allowed the short TI 
times to be achieved at the expense of spatial blurring especially for samples 
with higher [GaD]. Examples of the TI=20 ms for both 3T and 7T are shown in  
Figure 5.2e and 1f, respectively. The T1 measurement using the IR-TFL method 
was validated by using an inversion recovery spin echo acquisition with the AS 
phantom at 3T (IR-SE; TR, 3 s; TE, 11 ms; flip angle, 90°; acquisition matrix, 
256²; field of view, 300 mm2; slice thickness, 5mm; NEX= 1; TI, 23 ms). 
The average MR signal intensity (SI) and standard deviation for each 
region of interest (ROI) within each vial were obtained from the TFL images well 
within the vials to avoid partial volume effects with the wall of the container 
(Figure 5.1 e,f). For the inversion recovery sequence, the data was reconstructed 
in the real mode to allow negative signal intensities for fitting the T1 recovery 
curve. T2* effects resulting from global field inhomogeneities were minimized by 
performing B0 shimming within a localized coronal slab which included all the 
vials used in the analysis. The T1 values were obtained by performing an 
instrumental fit on the ROI SIs versus their respective TIs. The equation used to 
fit the data was SI(ROI) = A[0] × (1-2×exp(-A[1]×TI)) + A[2], where A[0], A[1] and 
A[2] are fit parameters such that T1 = 1/A[1]. The equation was fit to the data 
using the LMFit function within IDL (ITT, Visual Information Solutions, Boulder, 
CO) which employs a Levenberg-Marquardt algorithm to find a solution to the 
fitted parameters. A linear relationship between R1 and [GaD] was assumed to 
calculate r1. The equation used to fit the data was R1= r1 ∙ [GaD] + Intercept 
where r1 is the slope. The R1 vs. [GaD] data was fit using a linear instrumental fit 
function in Origin 8.1(OriginLab Corp., Northampton, MA). 
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5.4.6 T2* Measurement 
Multi-echo gradient echo acquisitions were performed to acquire the signal 
intensity data used to calculate T2*.Solvent and field strength dependent 
acquisition parameters are given in Table 5.1.  Varying TE ranges and the gaps 
between successive echo times (ΔTE) were chosen to measure the relaxation 
characteristics of each sample. At 3T, measurements on both AS and OVB were 
acquired with two concatenated acquisitions while for OVB at 7T, 3 interleaved 
acquisitions were acquired with a minimum effective ΔTE (ΔTEeff)  of 0.81 ms to 
capture the potentially rapidly decaying signals for high [GaD]. Acquisition 
parameters common to all acquisitions included a 10 degree flip angle and 280 
mm field of view. Images from the first TE of the multi-echo gradient echo 
acquisition and representative ROIs used for analysis are shown from the OVB 
phantom for both field strengths in Figure 5.1c and 1d, respectively.  
T2* values were obtained by performing a monoexponential instrumental fit 
of the ROI SIs versus their respective TEs using the function: SI(ROI) = 
A[0]×(exp(-A[1]×TE))+A[2], where A[0], A[1] and A[2] are fit parameters and A[1] 
= R2*. The optimization routine LMFIT was used within IDL to fit the equation to 
the SI amplitudes. Parameter A[2] was set by identifying the SI mean magnitude 
of the background noise. The mean noise was also used as a threshold to limit 
the range of included echo times for R2* estimation. To determine r2* relaxivity, 
the R2* versus [GaD] data was characterized by both a quadratic and a 
combination of both quadratic and linear functions.  First, the full range of [GaD] 
was fit solely with the quadratic function (R2* = A×[GaD]2 + B×[GaD] + C). 
Second, only lower [GaD] concentration were fit with the quadratic function while 
higher concentrations were fit with a linear relationship (R2* = A×[GaD] + B).  The 
R2* vs. [GaD] data was fit using the instrumental fit functions in Origin 8.1. The 
errors reported take into consideration the error propagation from volumetric 
analysis, nonlinear fit (T1 and T2* calculation) and linear/nonlinear fits (r1 and r2* 
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calculation). The standard errors of the fitting parameters were calculated from 
the square root of a main diagonal value of the variance-covariance matrix. 
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5.5 Results 
The native R1 and R2* values for OVB and AS have been summarized in Table 
5.2. The curve fits used to obtain r1 and r2* relaxivities for [GaD] in AS and OVB 
are shown in Figure 5.2. The r1 relaxivities for GaD in AS and OVB are shown in 
Table 5.3. For an increase in field strength from 3T to 7T there was a small 
(7.5%), but statistically significant (p = 0.045), decrease of GaD r1 in AS with no 
observable change in OVB r1 with an increase in field strength. The relationship 
between R2* and [GaD] for OVB and AS at 3T and 7T is shown in Figure 5.2. For 
an increase in field strength from 3T to 7T there was a 3% (p = 0.2) increase in 
GaD r2* relaxivity in AS (Table 5.4). In blood, the data was best described by a 
combined quadratic-linear relationship where a quadratic function better 
described the experimental data up to 1.98 mM while a linear function best 
described the R2* dependence on higher [GaD]. The most significant change in 
r2* was observed in OVB which increased over four-fold (for [GaD] beyond 2mM, 
p <<0.01). 
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Table 5.2 R1 and R2* values for Oxygenated Venous Blood (OVB) and Aqueous 
Solution (AS) at 3T and 7T at 37 ºC. 
Table 5.3 T1 relaxivities (r1) of Gd-DTPA in Oxygenated Venous Blood (OVB) and 
Aqueous Solution (AS) at 37 ºC for both 3 and 7T along with respective pO2, sO2 and 
Hematocrit (Hct) ranges used for the measurements. 
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Figure 5.2 Plots of R1 and R2* vs [GaD] for oxygenated venous blood (OVB) and 
aqueous solution (AS) at 3 and 7 T. Plots of relaxivity modeled with linear (red) and 
quadratic (blue) functions are shown. A linear model was used to calculate R1 relaxivity 
(r1) for 3 and 7 T in both AS (a, b) and OVB (c, d). A linear model was also used to 
calculate R2* relaxivity (r2*) in AS (e, f). To determine r2* in OVB, a quadratic function for 
[GaD] ≤ 2 mM and linear function for [GaD] ≥ 2 mM was found to characterize the data 
better than a quadratic fit alone over the whole range of [GaD] (g, h). 
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5.6 Discussion 
The r1 and r2* relaxivities of GaD depend on R1 and R2* which in turn depend on 
many factors such as macromolecular content, temperature, pH, magnetic field 
strength, acquisition parameters and oxygenation. To put the values obtained in 
this study in the context of previous work, r1 of GaD in water and blood obtained 
under similar experimental conditions are included in Tables 5.5 and 5.6, 
respectively. While previous studies investigating r2* of GaD have not been 
performed to date, native R2* in blood has been of great interest.  Values at 1.5T 
have shown arterial blood to have values  ranging from 3.94±0.50(126) to 
5.02±0.2(127) s-1. In the current study, large increases in native blood R2* were 
measured at 3T and 7T; 9.94±0.56 and 28.50±1.15 s-1, respectively. 
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5.6.1 Dependence of R2* on Oxygenation and GaD in 
Blood  
The characteristic linear relationship between R2* and [GaD] observed in AS was 
not observed in OVB.  Blood has three major distinguishing characteristics from a 
homogenous sample such as AS. First, compared to saline, blood experiences 
longer motional correlation times (slow motion) resulting in increased proton-
electron dipolar coupling. Second, it is multi-compartmental, consisting of the 
plasma and red blood cells (RBCs), where GaD (only present in the plasma) 
affects magnetic susceptibility differences between RBC and plasma. Third, it 
contains hemoglobin, the oxygen saturation of which also impacts the 
susceptibility mismatch between the two compartments.  In the case of fully 
oxygenated blood, the multiple compartments, and the dynamic processes 
between them, most likely results in the complex relationships observed between 
R2* and [GaD]. 
In the full range of physiological conditions, the oxygen dependence of 
blood R2* is usually  attributed to oxygenation based susceptibility of red blood 
cells (RBCs) where oxyhemoglobin is diamagnetic and de-oxyhemoglobin is 
paramagnetic, relative to blood plasma. In OVB, microscopic magnetic field 
gradients are set up between RBCs  and  plasma resulting in static and dynamic 
dephasing  of spins that can result in an increase in R2* (128). 
In deoxygenated blood, it was shown in a study by Blockley et al. that a 
quadratic behavior existed between R2* and [CA] (ProHance) (128). In this 
previous study a parabolic curve was fit to the data with the inflection point 
occurring at increasing concentrations with increasing field strength (1.0 mM and 
1.3 mM at 3.0T and 7.0T, respectively). This relationship was described as 
originating from an initial susceptibility difference between the paramagnetic 
RBCs and the diamagnetic plasma in deoxygenated blood. As the [CA] increases 
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there is likely an increase in the net paramagnetism of blood plasma which could 
lead to an averaging of the RBC versus plasma susceptibility variations. The 
inflection point in the R2* curve represented the point at which the CA increases 
the paramagnetism of the plasma to match that of the RBCs. Beyond this point, 
the susceptibility difference between plasma and blood again increased as did 
R2*.  
In the current study, oxygenated blood is investigated where the RBC are 
diamagnetic with respect to the blood plasma.  While there is no inflection point 
observed in this data there is still an observed quadratic relationship between R2* 
and [Gad] at lower concentrations from 0-2 mM, however a quadratic function did 
not sufficiently describe the data above this range.  The observed quadratic 
versus linear contributions was significantly different between 3T and 7T. This 
field dependence could be a result of varying contributions of susceptibility 
induced versus dipolar relaxation pathways further influenced by varying 
exchange and diffusion regimes with changes in [GaD]. 
While this study was not explicitly designed to elucidate the relaxation 
mechanisms involved, a brief discussion of factors that could contribute to the 
observed behavior follows. First, in the presence of GaD, which affects the 
relaxation rate constant of blood plasma predominantly, the regime of isothermal 
dynamics is shifted towards the intermediate motional regime (IMR) from the fast 
motional regime (FMR). In this study, because the apparent rate constants were 
altered by changing the concentration of GaD, and since GaD is only present in 
the plasma (site A) and not the RBC (site B), the “shutter speed”, i.e., |RA-RB|, of 
dynamic processes is varied. The dynamic processes which include exchange 
and diffusion which collectively result in dynamic averaging (DA) and are 
additionally characterized by the rate constant kDA  (129). In this particular case 
the regime of exchange or diffusion in local susceptibility gradients or 
intracellular-extracellular water transport are varied with the increase of the 
concentration of GaD (130). It appears that the presence of increasing GaD in 
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plasma shifts the regime of the dynamic process by modifying the intrinsic 
relaxation rate constants at specific magnetic sites A or B undergoing exchange 
or diffusion, as well as the apparent populations of sites A (i.e., plasma water 
protons interacting with GaD) or B (RBC water protons). Moving in this direction 
takes us from a quadratic to a linear relationship with increasing [GaD] where |RA 
– RB| >> kDA.
5.6.2 Effect of hyperoxygenation 
Based on initial in-house experiments, the OVB samples were necessarily 
hyperoxygenated in order to maintain the blood at arterial sO2 levels (sO2 > 94%) 
over the complete MR scan period. At our highest pO2 of 294 mmHg, Othee et al. 
have shown that the fraction of oxygen in the blood that is freely dissolved and 
not bound to hemoglobin is approximately 7% compared to 4% when exposed to 
room air (pO2 = 138 mmHg)(131). At 8.4T, the increase in dissolved oxygen from 
4% to7% would result in a minimal increase of 6% in blood T1 when measured at 
room temperature (131).  In another study, Blockley et al. reported R1 of whole 
blood versus (1-Y) at 3T and 7T, where ‘Y’ represents the fractional sO2 (128).  In 
our 3T studies where Y = 0.97 and 7T studies  where Y = 1, the predicted 
longitudinal relaxation times following Blockley’s relation would be 1730 ms and 
2041 ms, respectively. These values are in excellent agreement to our hyper-
oxygenated OVB T1 values of 1788.09±11.78 ms at 3T and 2055.43±14.00 ms at 
7T.  
The effect of hyperoxygenation on transverse relaxation is arguably much 
more complex. Molecular oxygen affects relaxation through paramagnetic 
interactions and, in addition, could influence magnetic susceptibility variations in 
the sample thus leading to different conditions of DA.  These mechanisms are 
challenging to characterize and beyond the scope of the presented work. While a 
potential limitation of the current study, hyperoxygenation was required to 
maintain arterial sO2 levels with the chosen experimental methods. 
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5.6.3 Acquisition Methods 
Alternative strategies, both in terms of the experimental setup and data 
acquisition were also considered for this study. However, the desire to obtain a 
wide distribution of concentrations at physiological temperature and sO2 led to 
the use of the IR-TFL sequence and rapidly imaging samples in an experimental 
setup with a concentration range from 0-5 mM. Determination of T1 values using 
the IR-TFL method was validated with those obtained using the IR-SE sequence 
with the final values only differing by 3%. 
As the Hct in the blood settles over the duration of the study, there is a 
change in the Hct content in the scanned MRI slice. An increase in Hct will lead 
to a higher value of r1. Using the IR-TFL sequence allowed the data to be 
acquired rapidly in comparison to the IR-SE method which decreased the total 
data acquisition time from 65 to 12 minutes. Secondly, the vials were positioned 
vertically to lengthen the distance over which settling would occur. The scan 
plane was also positioned through the center of the vials to minimize the pile up 
of Hct at the bottom or the absence of Hct at the top of the vile. Based on repeat 
data acquisitions, a 0.4% decrease in r1 per minute and a 0.3% increase in the 
slope of R2* vs. [GaD] per minute was found. Thus, the effect due to settling was 
minimal in this study. 
The challenges with the chosen acquisition methods were T2* blurring of 
the IR-TFL acquisition and the potential for a spatially varying B0 impacting 
primarily R1 and R2* calculations, respectively. To minimize the effect of T2* 
blurring, which increases with [GaD], ROIs well within each sample vial were 
used for R1 determination. Despite this strategy, slight variations from the linear 
relaxivity curve are still observed at the highest [GaD], (Figure 5.2 a-d). To 
address B0 homogeneity, a local B0 shim was used.  While a majority of the 
signal used for B0 shimming originated from the water bath, field perturbations 
from within and immediately around the samples had the potential of biasing the 
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global shim. For the AS samples, the expected linear relationship between R2* 
and [Gad] is observed for both 3T and 7T indicating that a reasonably 
homogeneous B0 field was obtained with the chosen shimming methods. 
This study provides important information on the susceptibility effects on 
R2* relaxation rate constants and their dependence on external static magnetic 
field in the presence of GaD. Importantly, because the susceptibility induced 
relaxation channel is one which significantly contributes to the free precession R2 
through its dependence on DA, our study indirectly provides insight into the free 
precession transverse relaxation of the blood in the presence of GaD as well. It 
should be emphasized that for accurate estimation of the intrinsic relaxation 
parameters from T2 measurements, the measurements of R2 relaxation 
dispersion using a Carr-Purcell-Meiboom-Gill (CPMG) acquisition is necessary.  
5.7 Conclusion 
The r1 of AS and OVB remained similar both between sample types and field 
strengths with only minor differences observed. The R2* relaxivity of AS was also 
similar at both 3T and 7T with only a 3% increase at the higher field strength. 
Furthermore, in AS, r2* values at 3T and 7T were only 22% and 36% higher than 
the respective r1 values. There was, on the other hand, a large effect of the multi-
compartmental nature of blood which resulted in an apparent nonlinear 
relationship between R2* and [GaD] and tremendous increases in r2* not 
observed the homogeneous AS phantom.  OVB r2* exhibited a large field 
dependence with an approximate four-fold increase in R2* relaxivity at 7T 
compared the 3T.  In addition, OVB r2* was twenty-fold higher at 3T and ninety-
fold higher at 7T compared to their respective r1 values.  
Knowledge of r1 and r2* relaxivities are paramount to using contrast agents 
at any field strength.  This study demonstrates sharply increasing r2* in the multi-
compartment blood samples greatly outpaces the relatively static r1 
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characteristics with increasing field strengths. Unless accounted for, studies 
relying on the typical T1 based contrast enhancement typically afforded by 
paramagnetic contrast administration at lower field strengths may obtain 
erroneous results.  
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Chapter 6 Conclusions 
6.1 Summary and Significance of Findings 
The American Cancer Society estimates that as of January 1, 2014 there are 
currently three million men living with PCa in the US alone (132). An estimated 
11.9 billion is spent each year in the US on PCa treatment (133). Over the past 
two decades, MRI has emerged as the leading imaging modality in detection and 
localization of PCa detection due to its excellent soft tissue contrast and its ability 
to generate tissue property dependent multi-parametric data (3). The work 
presented in this thesis leverages these advantages of MP-MRI in both high field 
and ultra-high field imaging in the development of methods for PCa detection.  
6.1.1 LATIS Image Registration 
The LATIS image registration method as detailed in Chapter 3 occupies a unique 
spot among Pathology-MR registration approaches found in literature. In this 
work we tackle the challenging problem of registering non-whole mount 
pathology to in vivo MRI data acquired with an endorectal coil in 35 cases and 
achieve registration accuracy of 1.54±0.65 mm. This registration accuracy along 
with DICE coefficient value of 0.9911±0.004 allows the confident use of 
pathology as a gold standard in our setup for developing predictive MRI models 
of disease.  Since work began on this project in 2010 there have been other 
attempts in this area. Prabu et al. (134) used a free form deformation and 
statistical deformation model based regularizer to register six cases leading to a 
mean . Patel et al. (92) used spatial weighted mutual information to register 7 
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PWM slices and report a mean RMS error of 1.65 mm and mean DICE 
coefficient of 0.83.  
Compared to other methods that require manual identification of 
numerous control points to facilitate accurate registration, LATIS offers the 
advantage of manually identifying large structures which is less labor and time 
intensive. More importantly, in some cases, selecting a sufficient number of 
control points may not even be possible. Selecting large structures rather than 
specific points is advantageous as it is makes LATIS potentially more robust in 
cases where the slicing or imaging plane are close but not exactly the same. 
While potentially less restrictive than other methods, LATIS still assumes that 
both source and target are approximately in the same plane through the prostate 
and still requires user input of identification and marking of structures on both 
datasets. Another limitation is that the assembling the individual digitized 
pathology images which compose the PWMHS involves user interaction and is 
suspect to variability. 
6.1.2 MP-MRI Predictive Models 
Four MP-MRI models for the prediction of PCa based on co-registered Pathology 
has been shown in Chapter 4. These models can be used to detect large and 
small lesions in the PZ (L5P_PZ), all cancer throughout the entire prostate 
(L3P_ALL) and all cancer versus non-cancer in the CG (L4P_CG and 
L3P_CGROI). The second model is most unique and arguably the most useful 
prospectively as no segmentation of the prostate would be needed prior to 
applying the model. The third and fourth models are also unique as PCa is most 
prevalent in the PZ and there has been limited work done in using MP-MRI 
models for prediction of PCa in CG alone. 
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While more work still needs to be done in this area a possible application 
of these models could be the generation of CBS Maps on a voxel-wise basis. 
These maps would be very useful in guiding biopsies and improving cancer 
management decisions.  
The uniqueness of our approach lies in the use of Pathology-MR 
coregistered datasets, inclusion of all cancer volumes > 0.19 cc and the use of 
voxel-wise analysis. With the LATIS based deformable co-registration (Chapter 
4) we have  reduce the bias in assessing the location and extent of disease in the
MRI slice compared to previously proposed methods. While groups have 
presented similar models for cancer detection, the data imparted by pathology to 
the MRI has been done manually. In comparison to our modeling approach that 
uses mapped pathology regions, these other  approaches are  prone  to  biases 
in  ROI  definition  due  to  subjectivity  in  operator interpretation of data within 
MP-MRI and Pathology images. 
Future studies will incorporate a T1-DESPOT1 based cutoff for voxel filtering. 
The clinical application of these models would require validation of different scanners 
and acquisition methods. The use of non coregistered datasets in model development 
might limit the application of these models in the clinic where the goal is to minimize user 
interactions in data generation. Co-registered datasets are usually not required as 
long as there is no patient motion.  However, in the presence of patient motion 
and in the case of DWI where EPI-based field distortions are present, registration 
between the MP-MRI datasets would be necessary. Algorithms incorporating 
Dynamic Field Correction (DFC) (135) have been developed to account for EPI-
based field distortions between the diffusion images. Anti-peristaltic drugs can be 
used to minimize patient motion. While some studies recommend injection of 
drugs like glucagon or hyoscine-N-butyl-bromide (HBB, butylscopolamine) for 
MR studies done at 1.5T (136,137), Roethke et al.(138) demonstrated that there 
was no significant effect of HBB administration on image quality for MRI studies 
at 3T. Other options for patient motion correction include the use of motion 
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correction algorithms(139) and MR sequences like PROPELLER(140). MRI-MRI 
Co-registration is an active area of investigation (141) and future work can 
incorporate available methods for this purpose.  
These models can be applied at many points in the PCa management. 
The proposed user-independent generation of cancer biomarker score maps on 
a voxel-wise basis would assist in guiding biopsies, improve management 
decisions, increase clinician confidence with suggesting active surveillance rather 
than receive definitive therapy to their patients, improve monitoring of men over 
time either on active surveillance or post therapy and target focal therapies as 
they become used more prevalently used clinically. While a complete analysis 
has not been done to date, each of these applications could have a tremendous 
impact by reducing treatment costs, improving outcomes and increasing quality 
of life for patients by avoiding unnecessary treatment and the commonly 
occurring side effects of incontinence and impotence.   
6.1.3 T1 and T2* Relaxivities of Gd-DTPA in Oxygenated 
Venous Blood and Aqueous Solution at 3 and 7T. 
Gd-DTPA (Magnevist™) is one of the most widely used MRI contrast agents 
(CAs) today. The relaxation enhancement of Gd-DTPA depends on its relaxivity 
which in turn depends on factors like magnetic field strength, macromolecular 
content, pH and temperature (12,142-144). Chapter 5 details work done to 
calculate r1 and r2* relaxivities of Gd-DTPA in oxygenated venous blood (OVB) 
and aqueous solution. The results show that the R1 relaxivity (r1) was relatively 
constant from 3T to 7T in OVB while the R2* relaxivity (r2*) increased four-fold. 
Based on these results, it can be calculated that sub-millisecond T2* relaxation 
times at 7T are possible with in-vivo Gd-DTPA concentrations ([GaD]) of 5 mM in 
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the blood which can be reached with injection rates of 3 ml/s (62). These effects 
could negatively impact contrast enhanced studies when performed at 7T if not 
accounted for in the sequence optimization and/or injection strategies. In general, 
the results from this study has  multiple  potential  uses including 1) optimization 
of sequence parameters 2) development of contrast injection paradigms 3) 
calibration  curves  to  determine  [Gd]  from  changes  in  T1   and  T2*  
relaxation  rates  (R1   and R2*).  
6.2   Future Work 
6.2.1 Correlation of MRI with Quantitative Pathology 
In addition to providing information regarding disease location and grade, digital 
pathology can also be processed to provide valuable quantitative information like 
percentages of tissue components (like nuclei, stroma, lumen and cytoplasm). It 
is therefore possible to correlate individual qMR parameters with quantitative 
pathology to better understand the correspondence between in-vivo MR 
parameters and anatomic/molecular pathologic status of tissue. An initial 
exploratory analysis was performed on an eight patient cohort (48) where T2-
SEMC and ADC (cancer and non-cancer) values were correlated to 
corresponding nuclear density values and grade obtained from pathology. Both 
T2-SEMC and ADC values for cancer were found to be lower than normal values 
in the CG and PZ (p<  0.0625  &  p<0.003,  respectively)  while  cancer nuclear 
densities  were  significantly  higher  (CG:  p<0.003,  PZ:  p<  0.003). Negative 
correlations between nuclear density and ADC (r = -0.98) and ADC and T2-
SEMC(r = -0.65) were found for tumor data (145). This study, as well as others 
(48), demonstrates that there are discernible pathologic features which correlate 
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with quantitative MRI metrics of PCa thus providing insight into the microstructure 
of the tissue. While it has been shown that Gleason score correlates positively to 
increased cellularity (146) and that nuclear density correlates with tumor 
aggressiveness (147,148), it is unknown how well these microscopic findings 
correlate to the macroscopic scale we currently operate in when imaging  with 
MRI.  The correlation of quantitative histopathological and pre-therapeutic MR 
parameters using Pathology-MR co-registered data sets, will help address these 
questions. 
6.2.2 Variation of the L5P_CGROI Model  
NCCG-ROI regions used in the L5P_CGROI model are obtained from user defined 
ROIs drawn on slices at least 9 mm away from regions of annotated cancer 
(Section 4.2.2). A direct comparison cannot be made currently between the 
L4P_CG and L5P_CGROI models as the non-cancer data belongs to different 
slices. To compare these models, user defined non cancer ROIs would need to 
be drawn with in NCCG regions from Data Pool III. This would enable a 
comparison of cancer in CG with non-cancer CG data obtained from 1) NCCG and 
2) ROIs drawn with in NCCG regions excluding the urethra, areas of fibromuscular
cap and post-biopsy hemorrhage.  
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